Caplyta

Overview

lumateperone

atypical antipsychotic

• CYP3A4 substrate
• CNS depression
• dopamine antagonist
• extrapyramidal effects
• hyperglycemic effects
• hyperthermia
• hyponatremia
• hypotensive effects
• lowers seizure threshold
• prolongs QT interval (conditional)
• serotonergic effects

Contraindicated

• pimozide
Caplyta (lumateperone)

+

pimozide

1 interaction

Contraindicated

lumateperone + pimozide

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia (additive effects)

• thioridazine
Caplyta (lumateperone)

+

thioridazine

1 interaction

Contraindicated

lumateperone + thioridazine

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, hyperthermia, hypotension, including orthostasis, syncope (additive effects)

Avoid/Use Alternative

• aldesleukin
Caplyta (lumateperone)

+

aldesleukin

1 interaction

Avoid/Use Alternative

lumateperone + aldesleukin

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment, severe or life-threatening hypotension (including orthostasis, syncope), seizures (additive effects)

• alfentanil
Caplyta (lumateperone)

+

alfentanil

1 interaction

Avoid/Use Alternative

lumateperone + alfentanil

use alternative or monitor BP, respiratory rate, serotonin syndrome sx, especially during initiation/titration; decr. dose of one or both drugs: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension (including orthostasis, syncope), serotonin syndrome (additive effects)

• amifampridine
Caplyta (lumateperone)

+

amifampridine

1 interaction

Avoid/Use Alternative

lumateperone + amifampridine

consider alternative: combo may incr. risk of seizures (additive effects)

• amphetamine
Caplyta (lumateperone)

+

amphetamine

1 interaction

Avoid/Use Alternative

lumateperone + amphetamine

consider alternative or monitor serotonin syndrome sx, especially during initiation/titration; decr. amphetamine start dose: combo may incr. risk of serotonin syndrome (additive effects)

• apalutamide
Caplyta (lumateperone)

+

apalutamide

1 interaction

Avoid/Use Alternative

lumateperone + apalutamide

avoid combo: combo may decr. lumateperone levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metabolism induced; additive effects)

• apomorphine
Caplyta (lumateperone)

+

apomorphine

1 interaction

Avoid/Use Alternative

lumateperone + apomorphine

use alternative or monitor ECG, BP: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, severe hypotension, including orthostasis, syncope; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• aripiprazole bimonthly injection
Caplyta (lumateperone)

+

aripiprazole bimonthly injection

1 interaction

Avoid/Use Alternative

lumateperone + aripiprazole bimonthly injection

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• aripiprazole lauroxil
Caplyta (lumateperone)

+

aripiprazole lauroxil

1 interaction

Avoid/Use Alternative

lumateperone + aripiprazole lauroxil

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• aripiprazole monthly injection
Caplyta (lumateperone)

+

aripiprazole monthly injection

1 interaction

Avoid/Use Alternative

lumateperone + aripiprazole monthly injection

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• aripiprazole oral
Caplyta (lumateperone)

+

aripiprazole oral

1 interaction

Avoid/Use Alternative

lumateperone + aripiprazole oral

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• armodafinil
Caplyta (lumateperone)

+

armodafinil

1 interaction

Avoid/Use Alternative

lumateperone + armodafinil

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• arsenic trioxide
Caplyta (lumateperone)

+

arsenic trioxide

1 interaction

Avoid/Use Alternative

lumateperone + arsenic trioxide

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• artemether/lumefantrine
Caplyta (lumateperone)

+

artemether/ lumefantrine

1 interaction

Avoid/Use Alternative

lumateperone + artemether/ lumefantrine

avoid combo: combo may decr. lumateperone levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metabolism induced; additive effects)

• asenapine
Caplyta (lumateperone)

+

asenapine

1 interaction

Avoid/Use Alternative

lumateperone + asenapine

use alternative or monitor ECG, BP: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• bedaquiline
Caplyta (lumateperone)

+

bedaquiline

1 interaction

Avoid/Use Alternative

lumateperone + bedaquiline

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• belzutifan
Caplyta (lumateperone)

+

belzutifan

1 interaction

Avoid/Use Alternative

lumateperone + belzutifan

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• bexarotene
Caplyta (lumateperone)

+

bexarotene

1 interaction

Avoid/Use Alternative

lumateperone + bexarotene

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• bosentan
Caplyta (lumateperone)

+

bosentan

1 interaction

Avoid/Use Alternative

lumateperone + bosentan

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• brexpiprazole
Caplyta (lumateperone)

+

brexpiprazole

1 interaction

Avoid/Use Alternative

lumateperone + brexpiprazole

use alternative or monitor BP: combo may incr. risk of hypotension (including orthostasis, syncope), CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, other adverse effects (additive effects, duplicate therapy)

• brigatinib
Caplyta (lumateperone)

+

brigatinib

1 interaction

Avoid/Use Alternative

lumateperone + brigatinib

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• bromocriptine
Caplyta (lumateperone)

+

bromocriptine

1 interaction

Avoid/Use Alternative

lumateperone + bromocriptine

use alternative: combo may incr. risk of CNS depression, psychomotor impairment, hypotension (including orthostasis, syncope), serotonin syndrome; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• buprenorphine
Caplyta (lumateperone)

+

buprenorphine

1 interaction

Avoid/Use Alternative

lumateperone + buprenorphine

use alternative or monitor respiratory rate, BP, serotonin syndrome sx, especially during initiation/titration; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension (including orthostasis, syncope), serotonin syndrome (additive effects)

• butalbital
Caplyta (lumateperone)

+

butalbital

1 interaction

Avoid/Use Alternative

lumateperone + butalbital

avoid combo: combo may decr. lumateperone levels, efficacy; may incr. risk of CNS and respiratory depression, psychomotor impairment (hepatic metabolism induced; additive effects)

• butorphanol
Caplyta (lumateperone)

+

butorphanol

1 interaction

Avoid/Use Alternative

lumateperone + butorphanol

use alternative or monitor BP, respiratory rate, serotonin syndrome sx, especially during initiation/titration; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, hypotension (including orthostasis, syncope), serotonin syndrome (additive effects)

• cabergoline
Caplyta (lumateperone)

+

cabergoline

1 interaction

Avoid/Use Alternative

lumateperone + cabergoline

use alternative: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• carbamazepine
Caplyta (lumateperone)

+

carbamazepine

1 interaction

Avoid/Use Alternative

lumateperone + carbamazepine

avoid combo: combo may decr. lumateperone levels, efficacy; may incr. risk of CNS depression, psychomotor impairment, hypotension (including syncope), hyponatremia, serotonin syndrome; may alter seizure control (hepatic metabolism induced; additive effects; antagonistic effects, lumateperone may decr. seizure threshold)

• cariprazine
Caplyta (lumateperone)

+

cariprazine

1 interaction

Avoid/Use Alternative

lumateperone + cariprazine

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• cenobamate
Caplyta (lumateperone)

+

cenobamate

1 interaction

Avoid/Use Alternative

lumateperone + cenobamate

avoid combo: combo may decr. lumateperone levels, efficacy; may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (hepatic metabolism induced; additive effects; antagonistic effects, lumateperone may decr. seizure threshold)

• ceritinib
Caplyta (lumateperone)

+

ceritinib

1 interaction

Avoid/Use Alternative

lumateperone + ceritinib

use alternative or monitor ECG; decr. lumateperone dose to 10.5 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• chloramphenicol
Caplyta (lumateperone)

+

chloramphenicol

1 interaction

Avoid/Use Alternative

lumateperone + chloramphenicol

use alternative or monitor ECG; decr. lumateperone dose to 10.5 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• cisapride
Caplyta (lumateperone)

+

cisapride

1 interaction

Avoid/Use Alternative

lumateperone + cisapride

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• citalopram
Caplyta (lumateperone)

+

citalopram

1 interaction

Avoid/Use Alternative

lumateperone + citalopram

use alternative or monitor sodium, ECG, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, serotonin syndrome, hyponatremia (additive effects)

• clobazam
Caplyta (lumateperone)

+

clobazam

1 interaction

Avoid/Use Alternative

lumateperone + clobazam

avoid combo: combo may decr. lumateperone levels, efficacy; may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope; may alter seizure control (hepatic metabolism induced; additive effects; antagonistic effects, lumateperone may decr. seizure threshold)

• clomipramine
Caplyta (lumateperone)

+

clomipramine

1 interaction

Avoid/Use Alternative

lumateperone + clomipramine

use alternative or monitor BP, sodium, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, seizures, hypotension (including orthostasis, syncope), hyponatremia, hyperthermia, serotonin syndrome (additive effects)

• clonidine
Caplyta (lumateperone)

+

clonidine

1 interaction

Avoid/Use Alternative

lumateperone + clonidine

if ADHD use, avoid combo; otherwise, monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• clozapine
Caplyta (lumateperone)

+

clozapine

1 interaction

Avoid/Use Alternative

lumateperone + clozapine

use alternative or monitor BP, HR: combo may incr. risk of hypotension (including orthostasis, syncope), CNS depression, psychomotor impairment, seizures, extrapyramidal symptoms, hyperthermia, other adverse effects (additive effects, duplicate therapy)

• codeine
Caplyta (lumateperone)

+

codeine

1 interaction

Avoid/Use Alternative

lumateperone + codeine

avoid combo if antitussive use; otherwise, use alternative or monitor respiratory rate, BP, serotonin syndrome sx, especially during initiation/titration; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension (including orthostasis, syncope), serotonin syndrome (additive effects)

• crizotinib
Caplyta (lumateperone)

+

crizotinib

1 interaction

Avoid/Use Alternative

lumateperone + crizotinib

use alternative or monitor ECG, electrolytes; decr. lumateperone dose to 21 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• cyclobenzaprine
Caplyta (lumateperone)

+

cyclobenzaprine

1 interaction

Avoid/Use Alternative

lumateperone + cyclobenzaprine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome, hyperthermia (additive effects)

• dabrafenib
Caplyta (lumateperone)

+

dabrafenib

1 interaction

Avoid/Use Alternative

lumateperone + dabrafenib

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• danshen
Caplyta (lumateperone)

+

danshen

1 interaction

Avoid/Use Alternative

lumateperone + danshen

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• darolutamide
Caplyta (lumateperone)

+

darolutamide

1 interaction

Avoid/Use Alternative

lumateperone + darolutamide

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• desipramine
Caplyta (lumateperone)

+

desipramine

1 interaction

Avoid/Use Alternative

lumateperone + desipramine

use alternative or monitor ECG, BP, sodium, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, hypotension (including orthostasis, syncope), hyponatremia, hyperthermia, serotonin syndrome (additive effects)

• desvenlafaxine
Caplyta (lumateperone)

+

desvenlafaxine

1 interaction

Avoid/Use Alternative

lumateperone + desvenlafaxine

use alternative or monitor sodium, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome, hyponatremia (additive effects)

• dexamethasone
Caplyta (lumateperone)

+

dexamethasone

1 interaction

Avoid/Use Alternative

lumateperone + dexamethasone

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• dextroamphetamine
Caplyta (lumateperone)

+

dextroamphetamine

1 interaction

Avoid/Use Alternative

lumateperone + dextroamphetamine

consider alternative or monitor serotonin syndrome sx, especially during initiation/titration; decr. dextroamphetamine start dose: combo may incr. risk of serotonin syndrome (additive effects)

• dicloxacillin
Caplyta (lumateperone)

+

dicloxacillin

1 interaction

Avoid/Use Alternative

lumateperone + dicloxacillin

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• dihydrocodeine
Caplyta (lumateperone)

+

dihydrocodeine

1 interaction

Avoid/Use Alternative

lumateperone + dihydrocodeine

use alternative or monitor respiratory rate, BP, serotonin syndrome sx, especially during initiation/titration; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension (including orthostasis, syncope), serotonin syndrome (additive effects)

• domperidone
Caplyta (lumateperone)

+

domperidone

1 interaction

Avoid/Use Alternative

lumateperone + domperidone

use alternative or monitor ECG, HR, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment (additive effects)

• doxylamine
Caplyta (lumateperone)

+

doxylamine

1 interaction

Avoid/Use Alternative

lumateperone + doxylamine

avoid combo if doxylamine use for pregnancy-related nausea/vomiting; otherwise, caution advised: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia (additive effects)

• duloxetine
Caplyta (lumateperone)

+

duloxetine

1 interaction

Avoid/Use Alternative

lumateperone + duloxetine

use alternative or monitor BP, sodium, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, hypotension (including orthostasis, syncope), serotonin syndrome, hyponatremia (additive effects)

• echinacea
Caplyta (lumateperone)

+

echinacea

1 interaction

Avoid/Use Alternative

lumateperone + echinacea

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• efavirenz
Caplyta (lumateperone)

+

efavirenz

1 interaction

Avoid/Use Alternative

lumateperone + efavirenz

avoid combo: combo may decr. lumateperone levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metabolism induced; additive effects)

• elafibranor
Caplyta (lumateperone)

+

elafibranor

1 interaction

Avoid/Use Alternative

lumateperone + elafibranor

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• elagolix
Caplyta (lumateperone)

+

elagolix

1 interaction

Avoid/Use Alternative

lumateperone + elagolix

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• enasidenib
Caplyta (lumateperone)

+

enasidenib

1 interaction

Avoid/Use Alternative

lumateperone + enasidenib

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• encorafenib
Caplyta (lumateperone)

+

encorafenib

1 interaction

Avoid/Use Alternative

lumateperone + encorafenib

avoid combo: combo may decr. lumateperone levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metabolism induced; additive effects)

• enzalutamide
Caplyta (lumateperone)

+

enzalutamide

1 interaction

Avoid/Use Alternative

lumateperone + enzalutamide

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• ephedra
Caplyta (lumateperone)

+

ephedra

1 interaction

Avoid/Use Alternative

lumateperone + ephedra

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• escitalopram
Caplyta (lumateperone)

+

escitalopram

1 interaction

Avoid/Use Alternative

lumateperone + escitalopram

use alternative or monitor sodium, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome, hyponatremia (additive effects)

• eslicarbazepine acetate
Caplyta (lumateperone)

+

eslicarbazepine acetate

1 interaction

Avoid/Use Alternative

lumateperone + eslicarbazepine acetate

avoid combo: combo may decr. lumateperone levels, efficacy; may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (hepatic metabolism induced; additive effects; antagonistic effects, lumateperone may decr. seizure threshold)

• ethanol (alcoholic beverage)
Caplyta (lumateperone)

+

ethanol (alcoholic beverage)

1 interaction

Avoid/Use Alternative

lumateperone + ethanol (alcoholic beverage)

avoid combo: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• ethanol injection
Caplyta (lumateperone)

+

ethanol injection

1 interaction

Avoid/Use Alternative

lumateperone + ethanol injection

use alternative or monitor respiratory rate, BP: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• etravirine
Caplyta (lumateperone)

+

etravirine

1 interaction

Avoid/Use Alternative

lumateperone + etravirine

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• felbamate
Caplyta (lumateperone)

+

felbamate

1 interaction

Avoid/Use Alternative

lumateperone + felbamate

avoid combo: combo may decr. lumateperone levels, efficacy; may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (hepatic metabolism induced; additive effects; antagonistic effects, lumateperone may decr. seizure threshold)

• fentanyl
Caplyta (lumateperone)

+

fentanyl

1 interaction

Avoid/Use Alternative

lumateperone + fentanyl

use alternative or monitor respiratory rate, BP, serotonin syndrome sx, especially during initiation/titration; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension (including orthostasis, syncope), serotonin syndrome (additive effects)

• fexinidazole
Caplyta (lumateperone)

+

fexinidazole

1 interaction

Avoid/Use Alternative

lumateperone + fexinidazole

avoid combo during and x7 days after fexinidazole tx; if possible, do not initiate fexinidazole until 5 half-lives after lumateperone D/C: combo may decr. lumateperone levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metabolism induced; additive effects)

• fluoxetine
Caplyta (lumateperone)

+

fluoxetine

1 interaction

Avoid/Use Alternative

lumateperone + fluoxetine

use alternative or monitor sodium, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome, hyponatremia (additive effects)

• fluvoxamine
Caplyta (lumateperone)

+

fluvoxamine

1 interaction

Avoid/Use Alternative

lumateperone + fluvoxamine

use alternative or monitor sodium, ECG, serotonin syndrome sx, especially during initiation/titration: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, serotonin syndrome, hyponatremia, other adverse effects (hepatic metabolism inhibited, additive effects)

• fosamprenavir
Caplyta (lumateperone)

+

fosamprenavir

1 interaction

Avoid/Use Alternative

lumateperone + fosamprenavir

avoid combo: combo may incr. or decr. lumateperone levels, incr. risk of QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy (hepatic metabolism altered)

• fosfomycin injection
Caplyta (lumateperone)

+

fosfomycin injection

1 interaction

Avoid/Use Alternative

lumateperone + fosfomycin injection

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fosphenytoin
Caplyta (lumateperone)

+

fosphenytoin

1 interaction

Avoid/Use Alternative

lumateperone + fosphenytoin

avoid combo: combo may decr. lumateperone levels, efficacy; may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (hepatic metabolism induced; additive effects; antagonistic effects, lumateperone may decr. seizure threshold)

• garlic
Caplyta (lumateperone)

+

garlic

1 interaction

Avoid/Use Alternative

lumateperone + garlic

avoid combo w/ supplemental garlic; dietary intake OK: combo may decr. lumateperone levels, efficacy; may incr. risk of hypotension, including orthostasis, syncope (hepatic metabolism induced; additive effects)

• gepirone
Caplyta (lumateperone)

+

gepirone

1 interaction

Avoid/Use Alternative

lumateperone + gepirone

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• ginkgo
Caplyta (lumateperone)

+

ginkgo

1 interaction

Avoid/Use Alternative

lumateperone + ginkgo

avoid combo: combo may incr. or decr. lumateperone levels, incr. risk of QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy (hepatic metabolism altered; additive effects)

• ginseng, Asian
Caplyta (lumateperone)

+

ginseng, Asian

1 interaction

Avoid/Use Alternative

lumateperone + ginseng, Asian

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• glycerol phenylbutyrate
Caplyta (lumateperone)

+

glycerol phenylbutyrate

1 interaction

Avoid/Use Alternative

lumateperone + glycerol phenylbutyrate

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• granisetron
Caplyta (lumateperone)

+

granisetron

1 interaction

Avoid/Use Alternative

lumateperone + granisetron

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• grapefruit
Caplyta (lumateperone)

+

grapefruit

1 interaction

Avoid/Use Alternative

lumateperone + grapefruit

avoid grapefruit juice: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (GI metabolism inhibited)

• griseofulvin
Caplyta (lumateperone)

+

griseofulvin

1 interaction

Avoid/Use Alternative

lumateperone + griseofulvin

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• haloperidol
Caplyta (lumateperone)

+

haloperidol

1 interaction

Avoid/Use Alternative

lumateperone + haloperidol

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, extrapyramidal symptoms, hypotension, including orthostasis, syncope (additive effects)

• hydrocodone
Caplyta (lumateperone)

+

hydrocodone

1 interaction

Avoid/Use Alternative

lumateperone + hydrocodone

avoid combo if antitussive use; otherwise, use alternative or monitor BP, respiratory rate, serotonin syndrome sx, especially during initiation/titration; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension (including orthostasis, syncope), serotonin syndrome (additive effects)

• hydromorphone
Caplyta (lumateperone)

+

hydromorphone

1 interaction

Avoid/Use Alternative

lumateperone + hydromorphone

use alternative or monitor BP, respiratory rate, serotonin syndrome sx, especially during initiation/titration; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension (including orthostasis, syncope), serotonin syndrome (additive effects)

• hydroxychloroquine
Caplyta (lumateperone)

+

hydroxychloroquine

1 interaction

Avoid/Use Alternative

lumateperone + hydroxychloroquine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects)

• iloperidone
Caplyta (lumateperone)

+

iloperidone

1 interaction

Avoid/Use Alternative

lumateperone + iloperidone

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• isocarboxazid
Caplyta (lumateperone)

+

isocarboxazid

1 interaction

Avoid/Use Alternative

lumateperone + isocarboxazid

use alternative or monitor BP, serotonin syndrome sx during and x10 days after isocarboxazid use: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome, hypotension, including orthostasis, syncope (additive effects)

• isoniazid
Caplyta (lumateperone)

+

isoniazid

1 interaction

Avoid/Use Alternative

lumateperone + isoniazid

use alternative or monitor ECG, serotonin syndrome sx, especially during initiation/titration: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, serotonin syndrome, other adverse effects (hepatic metabolism inhibited, additive effects, isoniazid inhibits monoamine oxidase)

• ivosidenib
Caplyta (lumateperone)

+

ivosidenib

1 interaction

Avoid/Use Alternative

lumateperone + ivosidenib

avoid combo: combo may decr. lumateperone levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metabolism induced; additive effects)

• kava
Caplyta (lumateperone)

+

kava

1 interaction

Avoid/Use Alternative

lumateperone + kava

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms (additive effects)

• kratom
Caplyta (lumateperone)

+

kratom

1 interaction

Avoid/Use Alternative

lumateperone + kratom

use alternative or monitor respiratory rate, ECG: combo may incr. lumateperone levels, risk of profound CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• lefamulin
Caplyta (lumateperone)

+

lefamulin

1 interaction

Avoid/Use Alternative

lumateperone + lefamulin

use alternative or monitor ECG; decr. lumateperone dose to 21 mg qd: combo with oral lefamulin may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; combo with IV lefamulin may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metabolism inhibited, additive effects)

• levomilnacipran
Caplyta (lumateperone)

+

levomilnacipran

1 interaction

Avoid/Use Alternative

lumateperone + levomilnacipran

use alternative or monitor sodium, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome, hyponatremia (additive effects)

• levorphanol
Caplyta (lumateperone)

+

levorphanol

1 interaction

Avoid/Use Alternative

lumateperone + levorphanol

use alternative or monitor BP, respiratory rate, serotonin syndrome sx, especially during initiation/titration; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension (including orthostasis, syncope), serotonin syndrome (additive effects)

• linezolid
Caplyta (lumateperone)

+

linezolid

1 interaction

Avoid/Use Alternative

lumateperone + linezolid

use alternative or hold lumateperone if urgent use; monitor sodium, serotonin syndrome sx x2wk after lumateperone D/C or 24h after last linezolid dose: combo may incr. risk of hyponatremia, serotonin syndrome (additive effects, linezolid reversibly inhibits monoamine oxidase)

• lisdexamfetamine
Caplyta (lumateperone)

+

lisdexamfetamine

1 interaction

Avoid/Use Alternative

lumateperone + lisdexamfetamine

consider alternative or monitor serotonin syndrome sx, especially during initiation/titration; decr. lisdexamfetamine start dose: combo may incr. risk of serotonin syndrome (additive effects)

• lithium
Caplyta (lumateperone)

+

lithium

1 interaction

Avoid/Use Alternative

lumateperone + lithium

use alternative or monitor serotonin syndrome sx, especially during initiation/titration; D/C one or both drugs if encephalopathy occurs: combo may incr. risk of serotonin syndrome, encephalopathic syndrome, extrapyramidal symptoms (additive effects)

• lofexidine
Caplyta (lumateperone)

+

lofexidine

1 interaction

Avoid/Use Alternative

lumateperone + lofexidine

use alternative or monitor BP, ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• lonafarnib
Caplyta (lumateperone)

+

lonafarnib

1 interaction

Avoid/Use Alternative

lumateperone + lonafarnib

use alternative or monitor HR, ECG, electrolytes; decr. lumateperone dose to 10.5 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• lopinavir/ritonavir
Caplyta (lumateperone)

+

lopinavir/ ritonavir

1 interaction

Avoid/Use Alternative

lumateperone + lopinavir/ ritonavir

avoid combo: combo may incr. or decr. lumateperone levels, incr. risk of QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy (hepatic metabolism altered)

• lorlatinib
Caplyta (lumateperone)

+

lorlatinib

1 interaction

Avoid/Use Alternative

lumateperone + lorlatinib

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• lumacaftor/ivacaftor
Caplyta (lumateperone)

+

lumacaftor/ ivacaftor

1 interaction

Avoid/Use Alternative

lumateperone + lumacaftor/ ivacaftor

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• lumateperone
Caplyta (lumateperone)

+

lumateperone

1 interaction

Avoid/Use Alternative

lumateperone + lumateperone

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), serotonin syndrome, hyponatremia, other adverse effects (additive effects, duplicate therapy)

• lurasidone
Caplyta (lumateperone)

+

lurasidone

1 interaction

Avoid/Use Alternative

lumateperone + lurasidone

use alternative or monitor ECG, BP; consider lowest lurasidone start dose, titrate slowly: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, hypotension (including orthostasis, syncope), CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, other adverse effects (hepatic metabolism inhibited, additive effects, duplicate therapy)

• mavacamten
Caplyta (lumateperone)

+

mavacamten

1 interaction

Avoid/Use Alternative

lumateperone + mavacamten

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• meperidine
Caplyta (lumateperone)

+

meperidine

1 interaction

Avoid/Use Alternative

lumateperone + meperidine

use alternative or monitor BP, respiratory rate, serotonin syndrome sx, especially during initiation/titration; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension (including orthostasis, syncope), serotonin syndrome (additive effects)

• metaxalone
Caplyta (lumateperone)

+

metaxalone

1 interaction

Avoid/Use Alternative

lumateperone + metaxalone

use alternative or monitor respiratory rate, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, serotonin syndrome (additive effects)

• methadone
Caplyta (lumateperone)

+

methadone

1 interaction

Avoid/Use Alternative

lumateperone + methadone

use alternative or monitor ECG, respiratory rate, BP, serotonin syndrome sx, especially during initiation/titration; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of QT prolongation, cardiac arrhythmias, profound CNS and respiratory depression, psychomotor impairment, severe hypotension (including orthostasis, syncope), serotonin syndrome (additive effects)

• methamphetamine
Caplyta (lumateperone)

+

methamphetamine

1 interaction

Avoid/Use Alternative

lumateperone + methamphetamine

consider alternative or monitor serotonin syndrome sx, especially during initiation/titration; decr. methamphetamine start dose: combo may incr. risk of serotonin syndrome (additive effects)

• metoclopramide
Caplyta (lumateperone)

+

metoclopramide

1 interaction

Avoid/Use Alternative

lumateperone + metoclopramide

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome, neuroleptic malignant syndrome, extrapyramidal symptoms (additive effects)

• midazolam
Caplyta (lumateperone)

+

midazolam

1 interaction

Avoid/Use Alternative

lumateperone + midazolam

use alternative or monitor respiratory rate, BP; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope; may alter seizure control (additive effects; antagonistic effects, lumateperone may decr. seizure threshold)

• milnacipran
Caplyta (lumateperone)

+

milnacipran

1 interaction

Avoid/Use Alternative

lumateperone + milnacipran

use alternative or monitor sodium, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome, hyponatremia (additive effects)

• milsaperidone
Caplyta (lumateperone)

+

milsaperidone

1 interaction

Avoid/Use Alternative

lumateperone + milsaperidone

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• mirtazapine
Caplyta (lumateperone)

+

mirtazapine

1 interaction

Avoid/Use Alternative

lumateperone + mirtazapine

use alternative or monitor BP, sodium, serotonin syndrome sx, especially during initiation/titration; consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, hypotension (including orthostasis, syncope), hyponatremia, serotonin syndrome, hyperthermia (additive effects)

• mitapivat
Caplyta (lumateperone)

+

mitapivat

1 interaction

Avoid/Use Alternative

lumateperone + mitapivat

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• mitotane
Caplyta (lumateperone)

+

mitotane

1 interaction

Avoid/Use Alternative

lumateperone + mitotane

avoid combo: combo may decr. lumateperone levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metabolism induced; additive effects)

• mobocertinib
Caplyta (lumateperone)

+

mobocertinib

1 interaction

Avoid/Use Alternative

lumateperone + mobocertinib

avoid combo: combo may decr. lumateperone levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metabolism induced; additive effects)

• modafinil
Caplyta (lumateperone)

+

modafinil

1 interaction

Avoid/Use Alternative

lumateperone + modafinil

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• morphine
Caplyta (lumateperone)

+

morphine

1 interaction

Avoid/Use Alternative

lumateperone + morphine

use alternative or monitor BP, respiratory rate, serotonin syndrome sx, especially during initiation/titration; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension (including orthostasis, syncope), serotonin syndrome (additive effects)

• nafcillin
Caplyta (lumateperone)

+

nafcillin

1 interaction

Avoid/Use Alternative

lumateperone + nafcillin

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• nalbuphine
Caplyta (lumateperone)

+

nalbuphine

1 interaction

Avoid/Use Alternative

lumateperone + nalbuphine

use alternative or monitor BP, respiratory rate, serotonin syndrome sx, especially during initiation/titration; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension (including orthostasis, syncope), serotonin syndrome (additive effects)

• netupitant
Caplyta (lumateperone)

+

netupitant

1 interaction

Avoid/Use Alternative

lumateperone + netupitant

use alternative or monitor ECG; decr. lumateperone dose to 21 mg qd during and x1wk after (fos)netupitant tx: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• nevirapine
Caplyta (lumateperone)

+

nevirapine

1 interaction

Avoid/Use Alternative

lumateperone + nevirapine

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• nortriptyline
Caplyta (lumateperone)

+

nortriptyline

1 interaction

Avoid/Use Alternative

lumateperone + nortriptyline

use alternative or monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, hypotension (including orthostasis, syncope), hyperthermia, serotonin syndrome (additive effects)

• odevixibat
Caplyta (lumateperone)

+

odevixibat

1 interaction

Avoid/Use Alternative

lumateperone + odevixibat

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• olanzapine
Caplyta (lumateperone)

+

olanzapine

1 interaction

Avoid/Use Alternative

lumateperone + olanzapine

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• oliceridine
Caplyta (lumateperone)

+

oliceridine

1 interaction

Avoid/Use Alternative

lumateperone + oliceridine

use alternative or monitor respiratory rate, ECG, BP, serotonin syndrome sx, especially during initiation/titration; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, severe hypotension (including orthostasis, syncope), serotonin syndrome (additive effects)

• olutasidenib
Caplyta (lumateperone)

+

olutasidenib

1 interaction

Avoid/Use Alternative

lumateperone + olutasidenib

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism possibly induced)

• omaveloxolone
Caplyta (lumateperone)

+

omaveloxolone

1 interaction

Avoid/Use Alternative

lumateperone + omaveloxolone

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• ondansetron
Caplyta (lumateperone)

+

ondansetron

1 interaction

Avoid/Use Alternative

lumateperone + ondansetron

use alternative or monitor ECG, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of QT prolongation, cardiac arrhythmias, serotonin syndrome (additive effects)

• opium
Caplyta (lumateperone)

+

opium

1 interaction

Avoid/Use Alternative

lumateperone + opium

use alternative or monitor BP, respiratory rate, serotonin syndrome sx, especially during initiation/titration; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, serotonin syndrome, severe hypotension, including orthostasis, syncope (additive effects)

• oxcarbazepine
Caplyta (lumateperone)

+

oxcarbazepine

1 interaction

Avoid/Use Alternative

lumateperone + oxcarbazepine

avoid combo: combo may decr. lumateperone levels, efficacy; may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (hepatic metabolism induced; additive effects; antagonistic effects, lumateperone may decr. seizure threshold)

• oxybate
Caplyta (lumateperone)

+

oxybate

1 interaction

Avoid/Use Alternative

lumateperone + oxybate

use alternative or monitor respiratory rate; decr. dose of one or both drugs: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, hypotension, syncope (additive effects)

• oxycodone
Caplyta (lumateperone)

+

oxycodone

1 interaction

Avoid/Use Alternative

lumateperone + oxycodone

use alternative or monitor BP, respiratory rate, serotonin syndrome sx, especially during initiation/titration; decr. oxycodone start dose by at least 50%, consider decr. lumateperone dose, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension (including orthostasis, syncope), serotonin syndrome (additive effects)

• oxymorphone
Caplyta (lumateperone)

+

oxymorphone

1 interaction

Avoid/Use Alternative

lumateperone + oxymorphone

use alternative or monitor respiratory rate, BP, serotonin syndrome sx, especially during initiation/titration; decr. oxymorphone start dose by at least 50%, consider decr. lumateperone dose, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension (including orthostasis, syncope), serotonin syndrome (additive effects)

• pacritinib
Caplyta (lumateperone)

+

pacritinib

1 interaction

Avoid/Use Alternative

lumateperone + pacritinib

avoid combo: combo may decr. lumateperone levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metabolism induced; additive effects)

• paliperidone
Caplyta (lumateperone)

+

paliperidone

1 interaction

Avoid/Use Alternative

lumateperone + paliperidone

use alternative or monitor BP, ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• paroxetine
Caplyta (lumateperone)

+

paroxetine

1 interaction

Avoid/Use Alternative

lumateperone + paroxetine

use alternative or monitor sodium, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome, hyponatremia (additive effects)

• pentazocine
Caplyta (lumateperone)

+

pentazocine

1 interaction

Avoid/Use Alternative

lumateperone + pentazocine

use alternative or monitor BP, respiratory rate, serotonin syndrome sx, especially during initiation/titration; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension (including orthostasis, syncope), serotonin syndrome (additive effects)

• pentobarbital
Caplyta (lumateperone)

+

pentobarbital

1 interaction

Avoid/Use Alternative

lumateperone + pentobarbital

avoid combo: combo may decr. lumateperone levels, efficacy; may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope (hepatic metabolism induced; additive effects)

• perampanel
Caplyta (lumateperone)

+

perampanel

1 interaction

Avoid/Use Alternative

lumateperone + perampanel

avoid combo: combo may decr. lumateperone levels, efficacy if on perampanel 12 mg/day; may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (hepatic metabolism induced; additive effects; antagonistic effects, lumateperone may decr. seizure threshold)

• pexidartinib
Caplyta (lumateperone)

+

pexidartinib

1 interaction

Avoid/Use Alternative

lumateperone + pexidartinib

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• phenelzine
Caplyta (lumateperone)

+

phenelzine

1 interaction

Avoid/Use Alternative

lumateperone + phenelzine

use alternative or monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome, hypotension, including orthostasis, syncope (additive effects)

• phenobarbital
Caplyta (lumateperone)

+

phenobarbital

1 interaction

Avoid/Use Alternative

lumateperone + phenobarbital

avoid combo: combo may decr. lumateperone levels, efficacy; may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope; may alter seizure control (hepatic metabolism induced; additive effects; antagonistic effects, lumateperone may decr. seizure threshold)

• phenytoin
Caplyta (lumateperone)

+

phenytoin

1 interaction

Avoid/Use Alternative

lumateperone + phenytoin

avoid combo: combo may decr. lumateperone levels, efficacy; may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (hepatic metabolism induced; additive effects; antagonistic effects, lumateperone may decr. seizure threshold)

• pioglitazone
Caplyta (lumateperone)

+

pioglitazone

1 interaction

Avoid/Use Alternative

lumateperone + pioglitazone

avoid combo: combo may decr. lumateperone levels, efficacy; may decr. antidiabetic agent efficacy (hepatic metabolism induced; antagonistic effects)

• prednisone
Caplyta (lumateperone)

+

prednisone

1 interaction

Avoid/Use Alternative

lumateperone + prednisone

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• primidone
Caplyta (lumateperone)

+

primidone

1 interaction

Avoid/Use Alternative

lumateperone + primidone

avoid combo: combo may decr. lumateperone levels, efficacy; may incr. risk of CNS and respiratory depression, psychomotor impairment; may alter seizure control (hepatic metabolism induced; additive effects; antagonistic effects, lumateperone may decr. seizure threshold)

• procarbazine
Caplyta (lumateperone)

+

procarbazine

1 interaction

Avoid/Use Alternative

lumateperone + procarbazine

use alternative or monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome, hypotension, including orthostasis, syncope (additive effects, procarbazine inhibits monoamine oxidase)

• promethazine
Caplyta (lumateperone)

+

promethazine

1 interaction

Avoid/Use Alternative

lumateperone + promethazine

use alternative or monitor respiratory rate, BP; decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, seizures, extrapyramidal symptoms, hyperthermia, hypotension, including orthostasis, syncope (additive effects)

• quetiapine
Caplyta (lumateperone)

+

quetiapine

1 interaction

Avoid/Use Alternative

lumateperone + quetiapine

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• quizartinib
Caplyta (lumateperone)

+

quizartinib

1 interaction

Avoid/Use Alternative

lumateperone + quizartinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• rasagiline
Caplyta (lumateperone)

+

rasagiline

1 interaction

Avoid/Use Alternative

lumateperone + rasagiline

use alternative: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome, hypotension, including orthostasis, syncope; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• remifentanil
Caplyta (lumateperone)

+

remifentanil

1 interaction

Avoid/Use Alternative

lumateperone + remifentanil

use alternative or monitor BP, respiratory rate, serotonin syndrome sx, especially during initiation/titration; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension (including orthostasis, syncope), serotonin syndrome (additive effects)

• repotrectinib
Caplyta (lumateperone)

+

repotrectinib

1 interaction

Avoid/Use Alternative

lumateperone + repotrectinib

avoid combo: combo may decr. lumateperone levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metabolism induced; additive effects)

• rifabutin
Caplyta (lumateperone)

+

rifabutin

1 interaction

Avoid/Use Alternative

lumateperone + rifabutin

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• rifampin
Caplyta (lumateperone)

+

rifampin

1 interaction

Avoid/Use Alternative

lumateperone + rifampin

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• rifapentine
Caplyta (lumateperone)

+

rifapentine

1 interaction

Avoid/Use Alternative

lumateperone + rifapentine

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• risperidone
Caplyta (lumateperone)

+

risperidone

1 interaction

Avoid/Use Alternative

lumateperone + risperidone

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension (including orthostasis, syncope), other adverse effects (additive effects, duplicate therapy)

• ropeginterferon alfa-2b
Caplyta (lumateperone)

+

ropeginterferon alfa-2b

1 interaction

Avoid/Use Alternative

lumateperone + ropeginterferon alfa-2b

use alternative: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• rufinamide
Caplyta (lumateperone)

+

rufinamide

1 interaction

Avoid/Use Alternative

lumateperone + rufinamide

avoid combo: combo may decr. lumateperone levels, efficacy; may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (hepatic metabolism induced; additive effects; antagonistic effects, lumateperone may decr. seizure threshold)

• safinamide
Caplyta (lumateperone)

+

safinamide

1 interaction

Avoid/Use Alternative

lumateperone + safinamide

use alternative: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome, hypotension, including orthostasis, syncope; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• sarilumab
Caplyta (lumateperone)

+

sarilumab

1 interaction

Avoid/Use Alternative

lumateperone + sarilumab

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism altered; sarilumab may reverse inflammatory cytokine-induced downregulation of CYP450 enzymes resulting in relative induction of enzymes upon tx start and downregulation upon D/C)

• scopolamine
Caplyta (lumateperone)

+

scopolamine

1 interaction

Avoid/Use Alternative

lumateperone + scopolamine

use alternative: combo may increase risk of CNS depression, psychomotor impairment, hyperthermia, including life-threatening (additive effects)

• selegiline
Caplyta (lumateperone)

+

selegiline

1 interaction

Avoid/Use Alternative

lumateperone + selegiline

use alternative: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome, hypotension, including orthostasis, syncope; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• selegiline transdermal
Caplyta (lumateperone)

+

selegiline transdermal

1 interaction

Avoid/Use Alternative

lumateperone + selegiline transdermal

use alternative: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome, hypotension, including orthostasis, syncope; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• sertraline
Caplyta (lumateperone)

+

sertraline

1 interaction

Avoid/Use Alternative

lumateperone + sertraline

use alternative or monitor sodium, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome, hyponatremia (additive effects)

• sotalol
Caplyta (lumateperone)

+

sotalol

1 interaction

Avoid/Use Alternative

lumateperone + sotalol

use alternative or monitor ECG, BP: combo may incr. risk of QT prolongation, cardiac arrhythmias, hypotension, including orthostasis, syncope (additive effects)

• sotorasib
Caplyta (lumateperone)

+

sotorasib

1 interaction

Avoid/Use Alternative

lumateperone + sotorasib

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• St. John's wort
Caplyta (lumateperone)

+

St. John's wort

1 interaction

Avoid/Use Alternative

lumateperone + St. John's wort

avoid combo: combo may decr. lumateperone levels, efficacy; may incr. risk of serotonin syndrome (hepatic metabolism induced; additive effects)

• stiripentol
Caplyta (lumateperone)

+

stiripentol

1 interaction

Avoid/Use Alternative

lumateperone + stiripentol

avoid combo: combo may incr. or decr. lumateperone levels, incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects or decr. efficacy; may alter seizure control (hepatic metabolism inhibited; hepatic metabolism possibly induced; additive effects; antagonistic effects, lumateperone may decr. seizure threshold)

• sufentanil
Caplyta (lumateperone)

+

sufentanil

1 interaction

Avoid/Use Alternative

lumateperone + sufentanil

use alternative or monitor BP, respiratory rate, serotonin syndrome sx, especially during initiation/titration; decr. sufentanil start dose, consider decr. lumateperone dose, use lowest effective doses: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension (including orthostasis, syncope), serotonin syndrome (additive effects)

• sunvozertinib
Caplyta (lumateperone)

+

sunvozertinib

1 interaction

Avoid/Use Alternative

lumateperone + sunvozertinib

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• suzetrigine
Caplyta (lumateperone)

+

suzetrigine

1 interaction

Avoid/Use Alternative

lumateperone + suzetrigine

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• tapentadol
Caplyta (lumateperone)

+

tapentadol

1 interaction

Avoid/Use Alternative

lumateperone + tapentadol

use alternative or monitor respiratory rate, BP, serotonin syndrome symptoms, especially during initiation/titration; decrease dose of one or both drugs, use lowest effective doses and shortest duration of concomitant treatment: combo may increase risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension (including orthostasis, syncope), serotonin syndrome (additive effects)

• tazemetostat
Caplyta (lumateperone)

+

tazemetostat

1 interaction

Avoid/Use Alternative

lumateperone + tazemetostat

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• tecovirimat
Caplyta (lumateperone)

+

tecovirimat

1 interaction

Avoid/Use Alternative

lumateperone + tecovirimat

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• telotristat ethyl
Caplyta (lumateperone)

+

telotristat ethyl

1 interaction

Avoid/Use Alternative

lumateperone + telotristat ethyl

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• thalidomide
Caplyta (lumateperone)

+

thalidomide

1 interaction

Avoid/Use Alternative

lumateperone + thalidomide

use alternative or monitor BP; consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• tocilizumab
Caplyta (lumateperone)

+

tocilizumab

1 interaction

Avoid/Use Alternative

lumateperone + tocilizumab

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism altered; tocilizumab may reverse inflammatory cytokine-induced downregulation of CYP450 enzymes resulting in relative induction of enzymes)

• topiramate
Caplyta (lumateperone)

+

topiramate

1 interaction

Avoid/Use Alternative

lumateperone + topiramate

avoid combo, especially w/ topiramate doses >200 mg/day: combo may decr. lumateperone levels, efficacy; may incr. risk of CNS depression, psychomotor impairment, hyperthermia; may alter seizure control (hepatic metabolism induced; additive effects; antagonistic effects, lumateperone may decr. seizure threshold)

• toremifene
Caplyta (lumateperone)

+

toremifene

1 interaction

Avoid/Use Alternative

lumateperone + toremifene

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• tovorafenib
Caplyta (lumateperone)

+

tovorafenib

1 interaction

Avoid/Use Alternative

lumateperone + tovorafenib

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• tradipitant
Caplyta (lumateperone)

+

tradipitant

1 interaction

Avoid/Use Alternative

lumateperone + tradipitant

use alternative: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tramadol
Caplyta (lumateperone)

+

tramadol

1 interaction

Avoid/Use Alternative

lumateperone + tramadol

use alternative or monitor ECG, BP, respiratory rate, sodium, serotonin syndrome sx, especially during initiation/titration; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of QT prolongation, cardiac arrhythmias, profound CNS and respiratory depression, psychomotor impairment, seizures, severe hypotension (including orthostasis, syncope), severe hyponatremia, serotonin syndrome (additive effects)

• tranylcypromine
Caplyta (lumateperone)

+

tranylcypromine

1 interaction

Avoid/Use Alternative

lumateperone + tranylcypromine

use alternative or monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome, hypotension, including orthostasis, syncope (additive effects)

• trimethobenzamide
Caplyta (lumateperone)

+

trimethobenzamide

1 interaction

Avoid/Use Alternative

lumateperone + trimethobenzamide

use alternative or consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms (additive effects)

• trimipramine
Caplyta (lumateperone)

+

trimipramine

1 interaction

Avoid/Use Alternative

lumateperone + trimipramine

use alternative or monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, hypotension (including orthostasis, syncope), hyperthermia, serotonin syndrome (additive effects)

• vamorolone
Caplyta (lumateperone)

+

vamorolone

1 interaction

Avoid/Use Alternative

lumateperone + vamorolone

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism possibly induced)

• vandetanib
Caplyta (lumateperone)

+

vandetanib

1 interaction

Avoid/Use Alternative

lumateperone + vandetanib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• vemurafenib
Caplyta (lumateperone)

+

vemurafenib

1 interaction

Avoid/Use Alternative

lumateperone + vemurafenib

avoid combo: combo may decr. lumateperone levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metabolism induced; additive effects)

• venlafaxine
Caplyta (lumateperone)

+

venlafaxine

1 interaction

Avoid/Use Alternative

lumateperone + venlafaxine

use alternative or monitor sodium, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome, hyponatremia (additive effects)

• vilazodone
Caplyta (lumateperone)

+

vilazodone

1 interaction

Avoid/Use Alternative

lumateperone + vilazodone

use alternative or monitor sodium, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, hyponatremia, serotonin syndrome (additive effects)

• vinblastine
Caplyta (lumateperone)

+

vinblastine

1 interaction

Avoid/Use Alternative

lumateperone + vinblastine

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• vorasidenib
Caplyta (lumateperone)

+

vorasidenib

1 interaction

Avoid/Use Alternative

lumateperone + vorasidenib

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism possibly induced)

• vortioxetine
Caplyta (lumateperone)

+

vortioxetine

1 interaction

Avoid/Use Alternative

lumateperone + vortioxetine

use alternative or monitor sodium, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of hyponatremia, serotonin syndrome (additive effects)

• zanubrutinib
Caplyta (lumateperone)

+

zanubrutinib

1 interaction

Avoid/Use Alternative

lumateperone + zanubrutinib

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• ziprasidone
Caplyta (lumateperone)

+

ziprasidone

1 interaction

Avoid/Use Alternative

lumateperone + ziprasidone

use alternative or monitor ECG, BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, extrapyramidal symptoms, hypotension (including orthostasis, syncope), serotonin syndrome, hyperthermia, other adverse effects (additive effects, duplicate therapy)

• zuranolone
Caplyta (lumateperone)

+

zuranolone

1 interaction

Avoid/Use Alternative

lumateperone + zuranolone

use alternative or consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

Monitor/Modify Tx

• 5-HTP
Caplyta (lumateperone)

+

5-HTP

1 interaction

Monitor/Modify Tx

lumateperone + 5-HTP

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome (additive effects)

• acarbose
Caplyta (lumateperone)

+

acarbose

1 interaction

Monitor/Modify Tx

lumateperone + acarbose

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• acebutolol
Caplyta (lumateperone)

+

acebutolol

1 interaction

Monitor/Modify Tx

lumateperone + acebutolol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• adagrasib
Caplyta (lumateperone)

+

adagrasib

1 interaction

Monitor/Modify Tx

lumateperone + adagrasib

monitor ECG, electrolytes; decr. lumateperone dose to 10.5 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• alfuzosin
Caplyta (lumateperone)

+

alfuzosin

1 interaction

Monitor/Modify Tx

lumateperone + alfuzosin

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• aliskiren
Caplyta (lumateperone)

+

aliskiren

1 interaction

Monitor/Modify Tx

lumateperone + aliskiren

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• almotriptan
Caplyta (lumateperone)

+

almotriptan

1 interaction

Monitor/Modify Tx

lumateperone + almotriptan

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome (additive effects)

• alogliptin
Caplyta (lumateperone)

+

alogliptin

1 interaction

Monitor/Modify Tx

lumateperone + alogliptin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• alprazolam
Caplyta (lumateperone)

+

alprazolam

1 interaction

Monitor/Modify Tx

lumateperone + alprazolam

monitor respiratory rate, ECG, BP: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, CNS and respiratory depression, psychomotor impairment, hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited, additive effects)

• alprostadil intracavernous
Caplyta (lumateperone)

+

alprostadil intracavernous

1 interaction

Monitor/Modify Tx

lumateperone + alprostadil intracavernous

monitor BP: combo may increase risk of hypotension, including orthostasis, syncope (additive effects)

• amantadine
Caplyta (lumateperone)

+

amantadine

1 interaction

Monitor/Modify Tx

lumateperone + amantadine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia, hypotension, including orthostasis, syncope (additive effects)

• amifostine
Caplyta (lumateperone)

+

amifostine

1 interaction

Monitor/Modify Tx

lumateperone + amifostine

monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

• amiloride
Caplyta (lumateperone)

+

amiloride

1 interaction

Monitor/Modify Tx

lumateperone + amiloride

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• amiodarone
Caplyta (lumateperone)

+

amiodarone

1 interaction

Monitor/Modify Tx

lumateperone + amiodarone

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• amitriptyline
Caplyta (lumateperone)

+

amitriptyline

1 interaction

Monitor/Modify Tx

lumateperone + amitriptyline

monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, hypotension (including orthostasis, syncope), serotonin syndrome, hyperthermia (additive effects)

• amlodipine
Caplyta (lumateperone)

+

amlodipine

1 interaction

Monitor/Modify Tx

lumateperone + amlodipine

monitor ECG, BP: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited, additive effects)

• amoxapine
Caplyta (lumateperone)

+

amoxapine

1 interaction

Monitor/Modify Tx

lumateperone + amoxapine

monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, hypotension (including orthostasis, syncope), serotonin syndrome, hyperthermia (additive effects)

• anagrelide
Caplyta (lumateperone)

+

anagrelide

1 interaction

Monitor/Modify Tx

lumateperone + anagrelide

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• apraclonidine ophthalmic
Caplyta (lumateperone)

+

apraclonidine ophthalmic

1 interaction

Monitor/Modify Tx

lumateperone + apraclonidine ophthalmic

monitor BP if apraclonidine IOP adjunct use; postop use OK: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• aprepitant
Caplyta (lumateperone)

+

aprepitant

1 interaction

Monitor/Modify Tx

lumateperone + aprepitant

if aprepitant 3-day regimen, monitor ECG; decr. lumateperone dose to 21 mg qd; aprepitant single dose-regimen OK: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• aprocitentan
Caplyta (lumateperone)

+

aprocitentan

1 interaction

Monitor/Modify Tx

lumateperone + aprocitentan

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• articaine
Caplyta (lumateperone)

+

articaine

1 interaction

Monitor/Modify Tx

lumateperone + articaine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• asciminib
Caplyta (lumateperone)

+

asciminib

1 interaction

Monitor/Modify Tx

lumateperone + asciminib

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• atazanavir
Caplyta (lumateperone)

+

atazanavir

1 interaction

Monitor/Modify Tx

lumateperone + atazanavir

monitor ECG; decr. lumateperone dose to 10.5 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• atenolol
Caplyta (lumateperone)

+

atenolol

1 interaction

Monitor/Modify Tx

lumateperone + atenolol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• atorvastatin
Caplyta (lumateperone)

+

atorvastatin

1 interaction

Monitor/Modify Tx

lumateperone + atorvastatin

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• avacopan
Caplyta (lumateperone)

+

avacopan

1 interaction

Monitor/Modify Tx

lumateperone + avacopan

monitor ECG; decr. lumateperone dose to 21 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• avanafil
Caplyta (lumateperone)

+

avanafil

1 interaction

Monitor/Modify Tx

lumateperone + avanafil

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• azilsartan medoxomil
Caplyta (lumateperone)

+

azilsartan medoxomil

1 interaction

Monitor/Modify Tx

lumateperone + azilsartan medoxomil

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• azithromycin
Caplyta (lumateperone)

+

azithromycin

1 interaction

Monitor/Modify Tx

lumateperone + azithromycin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• baclofen intrathecal
Caplyta (lumateperone)

+

baclofen intrathecal

1 interaction

Monitor/Modify Tx

lumateperone + baclofen intrathecal

monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• belumosudil
Caplyta (lumateperone)

+

belumosudil

1 interaction

Monitor/Modify Tx

lumateperone + belumosudil

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• benazepril
Caplyta (lumateperone)

+

benazepril

1 interaction

Monitor/Modify Tx

lumateperone + benazepril

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• berberine
Caplyta (lumateperone)

+

berberine

1 interaction

Monitor/Modify Tx

lumateperone + berberine

monitor ECG, BP: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited, additive effects)

• berotralstat
Caplyta (lumateperone)

+

berotralstat

1 interaction

Monitor/Modify Tx

lumateperone + berotralstat

monitor ECG; decr. lumateperone dose to 21 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• betaxolol
Caplyta (lumateperone)

+

betaxolol

1 interaction

Monitor/Modify Tx

lumateperone + betaxolol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• betaxolol ophthalmic
Caplyta (lumateperone)

+

betaxolol ophthalmic

1 interaction

Monitor/Modify Tx

lumateperone + betaxolol ophthalmic

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• bethanechol
Caplyta (lumateperone)

+

bethanechol

1 interaction

Monitor/Modify Tx

lumateperone + bethanechol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• bexagliflozin
Caplyta (lumateperone)

+

bexagliflozin

1 interaction

Monitor/Modify Tx

lumateperone + bexagliflozin

monitor glucose, BP: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

• bicalutamide
Caplyta (lumateperone)

+

bicalutamide

1 interaction

Monitor/Modify Tx

lumateperone + bicalutamide

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• bisoprolol
Caplyta (lumateperone)

+

bisoprolol

1 interaction

Monitor/Modify Tx

lumateperone + bisoprolol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• black cohosh
Caplyta (lumateperone)

+

black cohosh

1 interaction

Monitor/Modify Tx

lumateperone + black cohosh

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• bortezomib
Caplyta (lumateperone)

+

bortezomib

1 interaction

Monitor/Modify Tx

lumateperone + bortezomib

monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

• brimonidine ophthalmic
Caplyta (lumateperone)

+

brimonidine ophthalmic

1 interaction

Monitor/Modify Tx

lumateperone + brimonidine ophthalmic

monitor BP if elevated IOP or presbyopia use; OTC ocular redness use OK: combo may increase risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• brimonidine topical
Caplyta (lumateperone)

+

brimonidine topical

1 interaction

Monitor/Modify Tx

lumateperone + brimonidine topical

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• bumetanide
Caplyta (lumateperone)

+

bumetanide

1 interaction

Monitor/Modify Tx

lumateperone + bumetanide

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• bupivacaine
Caplyta (lumateperone)

+

bupivacaine

1 interaction

Monitor/Modify Tx

lumateperone + bupivacaine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• bupivacaine liposomal
Caplyta (lumateperone)

+

bupivacaine liposomal

1 interaction

Monitor/Modify Tx

lumateperone + bupivacaine liposomal

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• bupropion
Caplyta (lumateperone)

+

bupropion

1 interaction

Monitor/Modify Tx

lumateperone + bupropion

consider lower bupropion doses: combo may incr. risk of seizures (additive effects)

• buspirone
Caplyta (lumateperone)

+

buspirone

1 interaction

Monitor/Modify Tx

lumateperone + buspirone

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome (additive effects)

• cabozantinib
Caplyta (lumateperone)

+

cabozantinib

1 interaction

Monitor/Modify Tx

lumateperone + cabozantinib

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• canagliflozin
Caplyta (lumateperone)

+

canagliflozin

1 interaction

Monitor/Modify Tx

lumateperone + canagliflozin

monitor BP, glucose: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

• candesartan cilexetil
Caplyta (lumateperone)

+

candesartan cilexetil

1 interaction

Monitor/Modify Tx

lumateperone + candesartan cilexetil

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• cannabis
Caplyta (lumateperone)

+

cannabis

1 interaction

Monitor/Modify Tx

lumateperone + cannabis

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• capivasertib
Caplyta (lumateperone)

+

capivasertib

1 interaction

Monitor/Modify Tx

lumateperone + capivasertib

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• captopril
Caplyta (lumateperone)

+

captopril

1 interaction

Monitor/Modify Tx

lumateperone + captopril

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• carteolol ophthalmic
Caplyta (lumateperone)

+

carteolol ophthalmic

1 interaction

Monitor/Modify Tx

lumateperone + carteolol ophthalmic

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• carvedilol
Caplyta (lumateperone)

+

carvedilol

1 interaction

Monitor/Modify Tx

lumateperone + carvedilol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• chlordiazepoxide
Caplyta (lumateperone)

+

chlordiazepoxide

1 interaction

Monitor/Modify Tx

lumateperone + chlordiazepoxide

monitor respiratory rate, BP: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• chloroprocaine
Caplyta (lumateperone)

+

chloroprocaine

1 interaction

Monitor/Modify Tx

lumateperone + chloroprocaine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• chloroquine
Caplyta (lumateperone)

+

chloroquine

1 interaction

Monitor/Modify Tx

lumateperone + chloroquine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, extrapyramidal symptoms (additive effects)

• chlorothiazide
Caplyta (lumateperone)

+

chlorothiazide

1 interaction

Monitor/Modify Tx

lumateperone + chlorothiazide

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• chlorpromazine
Caplyta (lumateperone)

+

chlorpromazine

1 interaction

Monitor/Modify Tx

lumateperone + chlorpromazine

monitor BP, consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension, including orthostasis, syncope (additive effects)

• chlorthalidone
Caplyta (lumateperone)

+

chlorthalidone

1 interaction

Monitor/Modify Tx

lumateperone + chlorthalidone

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• chlorzoxazone
Caplyta (lumateperone)

+

chlorzoxazone

1 interaction

Monitor/Modify Tx

lumateperone + chlorzoxazone

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

• cilostazol
Caplyta (lumateperone)

+

cilostazol

1 interaction

Monitor/Modify Tx

lumateperone + cilostazol

monitor BP, ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited, additive effects)

• cimetidine
Caplyta (lumateperone)

+

cimetidine

1 interaction

Monitor/Modify Tx

lumateperone + cimetidine

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• ciprofloxacin
Caplyta (lumateperone)

+

ciprofloxacin

1 interaction

Monitor/Modify Tx

lumateperone + ciprofloxacin

monitor ECG; decr. lumateperone dose to 21 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• clarithromycin
Caplyta (lumateperone)

+

clarithromycin

1 interaction

Monitor/Modify Tx

lumateperone + clarithromycin

monitor ECG; decr. lumateperone dose to 10.5 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• clevidipine
Caplyta (lumateperone)

+

clevidipine

1 interaction

Monitor/Modify Tx

lumateperone + clevidipine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• clofarabine
Caplyta (lumateperone)

+

clofarabine

1 interaction

Monitor/Modify Tx

lumateperone + clofarabine

monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

• clofazimine
Caplyta (lumateperone)

+

clofazimine

1 interaction

Monitor/Modify Tx

lumateperone + clofazimine

monitor ECG; decr. lumateperone dose to 21 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• clonazepam
Caplyta (lumateperone)

+

clonazepam

1 interaction

Monitor/Modify Tx

lumateperone + clonazepam

monitor respiratory rate, BP: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope; may alter seizure control (additive effects; antagonistic effects, lumateperone may decr. seizure threshold)

• clorazepate
Caplyta (lumateperone)

+

clorazepate

1 interaction

Monitor/Modify Tx

lumateperone + clorazepate

monitor BP, respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope; may alter seizure control (additive effects; antagonistic effects, lumateperone may decr. seizure threshold)

• clotrimazole oropharyngeal
Caplyta (lumateperone)

+

clotrimazole oropharyngeal

1 interaction

Monitor/Modify Tx

lumateperone + clotrimazole oropharyngeal

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• cobicistat
Caplyta (lumateperone)

+

cobicistat

1 interaction

Monitor/Modify Tx

lumateperone + cobicistat

monitor ECG; decr. lumateperone dose to 10.5 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• cocaine
Caplyta (lumateperone)

+

cocaine

1 interaction

Monitor/Modify Tx

lumateperone + cocaine

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• coenzyme Q-10
Caplyta (lumateperone)

+

coenzyme Q-10

1 interaction

Monitor/Modify Tx

lumateperone + coenzyme Q-10

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• colesevelam
Caplyta (lumateperone)

+

colesevelam

1 interaction

Monitor/Modify Tx

lumateperone + colesevelam

monitor glucose in type 2 diabetes mellitus pts: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• conivaptan
Caplyta (lumateperone)

+

conivaptan

1 interaction

Monitor/Modify Tx

lumateperone + conivaptan

monitor ECG; decr. lumateperone dose to 21 mg qd during and x7 days after conivaptan tx: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• cranberry
Caplyta (lumateperone)

+

cranberry

1 interaction

Monitor/Modify Tx

lumateperone + cranberry

monitor ECG, especially w/ large amounts of cranberry: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (GI metabolism inhibited)

• cyclosporine
Caplyta (lumateperone)

+

cyclosporine

1 interaction

Monitor/Modify Tx

lumateperone + cyclosporine

monitor ECG; decr. lumateperone dose to 21 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• danazol
Caplyta (lumateperone)

+

danazol

1 interaction

Monitor/Modify Tx

lumateperone + danazol

monitor ECG; decr. lumateperone dose to 21 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• dapagliflozin
Caplyta (lumateperone)

+

dapagliflozin

1 interaction

Monitor/Modify Tx

lumateperone + dapagliflozin

monitor BP, glucose: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

• daridorexant
Caplyta (lumateperone)

+

daridorexant

1 interaction

Monitor/Modify Tx

lumateperone + daridorexant

monitor ECG; consider decr. dose of one or both drugs: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

• darunavir
Caplyta (lumateperone)

+

darunavir

1 interaction

Monitor/Modify Tx

lumateperone + darunavir

monitor ECG; decr. lumateperone dose to 21 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• degarelix
Caplyta (lumateperone)

+

degarelix

1 interaction

Monitor/Modify Tx

lumateperone + degarelix

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• denileukin diftitox
Caplyta (lumateperone)

+

denileukin diftitox

1 interaction

Monitor/Modify Tx

lumateperone + denileukin diftitox

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• desflurane
Caplyta (lumateperone)

+

desflurane

1 interaction

Monitor/Modify Tx

lumateperone + desflurane

monitor ECG, BP, respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• dexmedetomidine
Caplyta (lumateperone)

+

dexmedetomidine

1 interaction

Monitor/Modify Tx

lumateperone + dexmedetomidine

monitor BP, HR, ECG, electrolytes; consider decr. dose of one or both drugs: combo may incr. risk of QT prolongation, cardiac arrhythmias, hypotension (including orthostasis, syncope), CNS depression, psychomotor impairment (additive effects)

• dexmedetomidine injection
Caplyta (lumateperone)

+

dexmedetomidine injection

1 interaction

Monitor/Modify Tx

lumateperone + dexmedetomidine injection

monitor ECG, BP, respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS and respiratory depression, psychomotor impairment, severe or life-threatening hypotension, including orthostasis, syncope (additive effects)

• dexmethylphenidate
Caplyta (lumateperone)

+

dexmethylphenidate

1 interaction

Monitor/Modify Tx

lumateperone + dexmethylphenidate

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• dextromethorphan
Caplyta (lumateperone)

+

dextromethorphan

1 interaction

Monitor/Modify Tx

lumateperone + dextromethorphan

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• diazepam
Caplyta (lumateperone)

+

diazepam

1 interaction

Monitor/Modify Tx

lumateperone + diazepam

monitor respiratory rate, BP; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope; may alter seizure control (additive effects; antagonistic effects, lumateperone may decr. seizure threshold)

• dihydroergotamine
Caplyta (lumateperone)

+

dihydroergotamine

1 interaction

Monitor/Modify Tx

lumateperone + dihydroergotamine

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• diltiazem
Caplyta (lumateperone)

+

diltiazem

1 interaction

Monitor/Modify Tx

lumateperone + diltiazem

monitor BP, ECG; decr. lumateperone dose to 21 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited, additive effects)

• dinutuximab
Caplyta (lumateperone)

+

dinutuximab

1 interaction

Monitor/Modify Tx

lumateperone + dinutuximab

monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

• diosmin
Caplyta (lumateperone)

+

diosmin

1 interaction

Monitor/Modify Tx

lumateperone + diosmin

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• dipyridamole
Caplyta (lumateperone)

+

dipyridamole

1 interaction

Monitor/Modify Tx

lumateperone + dipyridamole

monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

• disopyramide
Caplyta (lumateperone)

+

disopyramide

1 interaction

Monitor/Modify Tx

lumateperone + disopyramide

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, hyperthermia (additive effects)

• dofetilide
Caplyta (lumateperone)

+

dofetilide

1 interaction

Monitor/Modify Tx

lumateperone + dofetilide

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• donepezil
Caplyta (lumateperone)

+

donepezil

1 interaction

Monitor/Modify Tx

lumateperone + donepezil

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dordaviprone
Caplyta (lumateperone)

+

dordaviprone

1 interaction

Monitor/Modify Tx

lumateperone + dordaviprone

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• doxazosin
Caplyta (lumateperone)

+

doxazosin

1 interaction

Monitor/Modify Tx

lumateperone + doxazosin

monitor BP, especially during doxazosin initiation/titration: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• doxepin
Caplyta (lumateperone)

+

doxepin

1 interaction

Monitor/Modify Tx

lumateperone + doxepin

monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, hypotension (including orthostasis, syncope), hyperthermia, serotonin syndrome (additive effects)

• doxepin topical
Caplyta (lumateperone)

+

doxepin topical

1 interaction

Monitor/Modify Tx

lumateperone + doxepin topical

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome, hyperthermia (additive effects)

• dronabinol
Caplyta (lumateperone)

+

dronabinol

1 interaction

Monitor/Modify Tx

lumateperone + dronabinol

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• dronedarone
Caplyta (lumateperone)

+

dronedarone

1 interaction

Monitor/Modify Tx

lumateperone + dronedarone

monitor ECG; decr. lumateperone dose to 21 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• droperidol
Caplyta (lumateperone)

+

droperidol

1 interaction

Monitor/Modify Tx

lumateperone + droperidol

monitor ECG, decr. dose of one or both drugs: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment (additive effects)

• dulaglutide
Caplyta (lumateperone)

+

dulaglutide

1 interaction

Monitor/Modify Tx

lumateperone + dulaglutide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• duvelisib
Caplyta (lumateperone)

+

duvelisib

1 interaction

Monitor/Modify Tx

lumateperone + duvelisib

monitor ECG; decr. lumateperone dose to 21 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• eletriptan
Caplyta (lumateperone)

+

eletriptan

1 interaction

Monitor/Modify Tx

lumateperone + eletriptan

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome (additive effects)

• elinzanetant
Caplyta (lumateperone)

+

elinzanetant

1 interaction

Monitor/Modify Tx

lumateperone + elinzanetant

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

• empagliflozin
Caplyta (lumateperone)

+

empagliflozin

1 interaction

Monitor/Modify Tx

lumateperone + empagliflozin

monitor BP, glucose: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

• enalapril
Caplyta (lumateperone)

+

enalapril

1 interaction

Monitor/Modify Tx

lumateperone + enalapril

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• enalaprilat
Caplyta (lumateperone)

+

enalaprilat

1 interaction

Monitor/Modify Tx

lumateperone + enalaprilat

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• entacapone
Caplyta (lumateperone)

+

entacapone

1 interaction

Monitor/Modify Tx

lumateperone + entacapone

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• entrectinib
Caplyta (lumateperone)

+

entrectinib

1 interaction

Monitor/Modify Tx

lumateperone + entrectinib

monitor ECG, BP: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited, additive effects)

• epirubicin
Caplyta (lumateperone)

+

epirubicin

1 interaction

Monitor/Modify Tx

lumateperone + epirubicin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• eplerenone
Caplyta (lumateperone)

+

eplerenone

1 interaction

Monitor/Modify Tx

lumateperone + eplerenone

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• epoprostenol
Caplyta (lumateperone)

+

epoprostenol

1 interaction

Monitor/Modify Tx

lumateperone + epoprostenol

monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

• ergotamine
Caplyta (lumateperone)

+

ergotamine

1 interaction

Monitor/Modify Tx

lumateperone + ergotamine

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• eribulin
Caplyta (lumateperone)

+

eribulin

1 interaction

Monitor/Modify Tx

lumateperone + eribulin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ertugliflozin
Caplyta (lumateperone)

+

ertugliflozin

1 interaction

Monitor/Modify Tx

lumateperone + ertugliflozin

monitor BP, glucose: combo may incr. risk of hypotension, including orthostasis, syncope; may decr. antidiabetic agent efficacy (additive effects; antagonistic effects)

• erythromycin
Caplyta (lumateperone)

+

erythromycin

1 interaction

Monitor/Modify Tx

lumateperone + erythromycin

monitor ECG; decr. lumateperone dose to 21 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• esketamine
Caplyta (lumateperone)

+

esketamine

1 interaction

Monitor/Modify Tx

lumateperone + esketamine

monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• esmolol
Caplyta (lumateperone)

+

esmolol

1 interaction

Monitor/Modify Tx

lumateperone + esmolol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• estazolam
Caplyta (lumateperone)

+

estazolam

1 interaction

Monitor/Modify Tx

lumateperone + estazolam

monitor BP, respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• eszopiclone
Caplyta (lumateperone)

+

eszopiclone

1 interaction

Monitor/Modify Tx

lumateperone + eszopiclone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ethacrynic acid
Caplyta (lumateperone)

+

ethacrynic acid

1 interaction

Monitor/Modify Tx

lumateperone + ethacrynic acid

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• ethanol (in some formulations)
Caplyta (lumateperone)

+

ethanol (in some formulations)

1 interaction

Monitor/Modify Tx

lumateperone + ethanol (in some formulations)

monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• ethinyl estradiol (contraceptive)
Caplyta (lumateperone)

+

ethinyl estradiol (contraceptive)

1 interaction

Monitor/Modify Tx

lumateperone + ethinyl estradiol (contraceptive)

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• etomidate
Caplyta (lumateperone)

+

etomidate

1 interaction

Monitor/Modify Tx

lumateperone + etomidate

monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• etripamil nasal
Caplyta (lumateperone)

+

etripamil nasal

1 interaction

Monitor/Modify Tx

lumateperone + etripamil nasal

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• everolimus
Caplyta (lumateperone)

+

everolimus

1 interaction

Monitor/Modify Tx

lumateperone + everolimus

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• exenatide
Caplyta (lumateperone)

+

exenatide

1 interaction

Monitor/Modify Tx

lumateperone + exenatide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• fedratinib
Caplyta (lumateperone)

+

fedratinib

1 interaction

Monitor/Modify Tx

lumateperone + fedratinib

monitor ECG; decr. lumateperone dose to 21 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• felodipine
Caplyta (lumateperone)

+

felodipine

1 interaction

Monitor/Modify Tx

lumateperone + felodipine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• fenfluramine
Caplyta (lumateperone)

+

fenfluramine

1 interaction

Monitor/Modify Tx

lumateperone + fenfluramine

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome; may alter seizure control (additive effects; antagonistic effects, lumateperone may decr. seizure threshold)

• fenoldopam
Caplyta (lumateperone)

+

fenoldopam

1 interaction

Monitor/Modify Tx

lumateperone + fenoldopam

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• ferumoxytol
Caplyta (lumateperone)

+

ferumoxytol

1 interaction

Monitor/Modify Tx

lumateperone + ferumoxytol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• finerenone
Caplyta (lumateperone)

+

finerenone

1 interaction

Monitor/Modify Tx

lumateperone + finerenone

monitor ECG if on finerenone 40 mg/day: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• flaxseed
Caplyta (lumateperone)

+

flaxseed

1 interaction

Monitor/Modify Tx

lumateperone + flaxseed

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• flecainide
Caplyta (lumateperone)

+

flecainide

1 interaction

Monitor/Modify Tx

lumateperone + flecainide

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• flibanserin
Caplyta (lumateperone)

+

flibanserin

1 interaction

Monitor/Modify Tx

lumateperone + flibanserin

monitor ECG, BP: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, severe hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited, additive effects)

• fluconazole
Caplyta (lumateperone)

+

fluconazole

1 interaction

Monitor/Modify Tx

lumateperone + fluconazole

monitor ECG; decr. lumateperone dose to 21 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• fluorouracil
Caplyta (lumateperone)

+

fluorouracil

1 interaction

Monitor/Modify Tx

lumateperone + fluorouracil

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fluphenazine
Caplyta (lumateperone)

+

fluphenazine

1 interaction

Monitor/Modify Tx

lumateperone + fluphenazine

monitor BP; consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension, including orthostasis, syncope (additive effects)

• flurazepam
Caplyta (lumateperone)

+

flurazepam

1 interaction

Monitor/Modify Tx

lumateperone + flurazepam

monitor BP, respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• fosaprepitant
Caplyta (lumateperone)

+

fosaprepitant

1 interaction

Monitor/Modify Tx

lumateperone + fosaprepitant

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• fosinopril
Caplyta (lumateperone)

+

fosinopril

1 interaction

Monitor/Modify Tx

lumateperone + fosinopril

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• foslevodopa
Caplyta (lumateperone)

+

foslevodopa

1 interaction

Monitor/Modify Tx

lumateperone + foslevodopa

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• fostamatinib
Caplyta (lumateperone)

+

fostamatinib

1 interaction

Monitor/Modify Tx

lumateperone + fostamatinib

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• frovatriptan
Caplyta (lumateperone)

+

frovatriptan

1 interaction

Monitor/Modify Tx

lumateperone + frovatriptan

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome (additive effects)

• furosemide
Caplyta (lumateperone)

+

furosemide

1 interaction

Monitor/Modify Tx

lumateperone + furosemide

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• gabapentin
Caplyta (lumateperone)

+

gabapentin

1 interaction

Monitor/Modify Tx

lumateperone + gabapentin

monitor respiratory rate; consider decreasing gabapentin dose: combo may increase risk of profound CNS and respiratory depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, lumateperone may decrease seizure threshold)

• gabapentin enacarbil
Caplyta (lumateperone)

+

gabapentin enacarbil

1 interaction

Monitor/Modify Tx

lumateperone + gabapentin enacarbil

monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

• gepotidacin
Caplyta (lumateperone)

+

gepotidacin

1 interaction

Monitor/Modify Tx

lumateperone + gepotidacin

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• gilteritinib
Caplyta (lumateperone)

+

gilteritinib

1 interaction

Monitor/Modify Tx

lumateperone + gilteritinib

monitor ECG, electrolytes, BP: combo may incr. risk of QT prolongation, cardiac arrhythmias, hypotension, including orthostasis, syncope (additive effects)

• givinostat
Caplyta (lumateperone)

+

givinostat

1 interaction

Monitor/Modify Tx

lumateperone + givinostat

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (GI metabolism inhibited)

• givosiran
Caplyta (lumateperone)

+

givosiran

1 interaction

Monitor/Modify Tx

lumateperone + givosiran

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited; givosiran effects on hepatic heme biosynthesis may reduce CYP450 enzyme activity)

• glasdegib
Caplyta (lumateperone)

+

glasdegib

1 interaction

Monitor/Modify Tx

lumateperone + glasdegib

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• glecaprevir
Caplyta (lumateperone)

+

glecaprevir

1 interaction

Monitor/Modify Tx

lumateperone + glecaprevir

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• glimepiride
Caplyta (lumateperone)

+

glimepiride

1 interaction

Monitor/Modify Tx

lumateperone + glimepiride

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• glipizide
Caplyta (lumateperone)

+

glipizide

1 interaction

Monitor/Modify Tx

lumateperone + glipizide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• glyburide
Caplyta (lumateperone)

+

glyburide

1 interaction

Monitor/Modify Tx

lumateperone + glyburide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• goldenseal
Caplyta (lumateperone)

+

goldenseal

1 interaction

Monitor/Modify Tx

lumateperone + goldenseal

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• goserelin
Caplyta (lumateperone)

+

goserelin

1 interaction

Monitor/Modify Tx

lumateperone + goserelin

PROSTATE CANCER: monitor ECG, electrolytes; ALL OTHER INDICATIONS: consider monitoring ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• grazoprevir
Caplyta (lumateperone)

+

grazoprevir

1 interaction

Monitor/Modify Tx

lumateperone + grazoprevir

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• guanfacine
Caplyta (lumateperone)

+

guanfacine

1 interaction

Monitor/Modify Tx

lumateperone + guanfacine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• histrelin
Caplyta (lumateperone)

+

histrelin

1 interaction

Monitor/Modify Tx

lumateperone + histrelin

consider monitoring ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• hydralazine
Caplyta (lumateperone)

+

hydralazine

1 interaction

Monitor/Modify Tx

lumateperone + hydralazine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• hydrochlorothiazide
Caplyta (lumateperone)

+

hydrochlorothiazide

1 interaction

Monitor/Modify Tx

lumateperone + hydrochlorothiazide

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• hydroxyzine
Caplyta (lumateperone)

+

hydroxyzine

1 interaction

Monitor/Modify Tx

lumateperone + hydroxyzine

monitor ECG; consider decr. dose of one or both drugs: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, hyperthermia (additive effects)

• ibutilide
Caplyta (lumateperone)

+

ibutilide

1 interaction

Monitor/Modify Tx

lumateperone + ibutilide

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• idelalisib
Caplyta (lumateperone)

+

idelalisib

1 interaction

Monitor/Modify Tx

lumateperone + idelalisib

monitor ECG; decr. lumateperone dose to 10.5 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• ifosfamide
Caplyta (lumateperone)

+

ifosfamide

1 interaction

Monitor/Modify Tx

lumateperone + ifosfamide

D/C one or both drugs if encephalopathy occurs; otherwise, caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• iloprost
Caplyta (lumateperone)

+

iloprost

1 interaction

Monitor/Modify Tx

lumateperone + iloprost

monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

• imatinib
Caplyta (lumateperone)

+

imatinib

1 interaction

Monitor/Modify Tx

lumateperone + imatinib

monitor ECG; decr. lumateperone dose to 21 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• imipramine
Caplyta (lumateperone)

+

imipramine

1 interaction

Monitor/Modify Tx

lumateperone + imipramine

monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, (hypotension, including orthostasis, syncope), hyperthermia, serotonin syndrome (additive effects)

• indapamide
Caplyta (lumateperone)

+

indapamide

1 interaction

Monitor/Modify Tx

lumateperone + indapamide

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• inotuzumab ozogamicin
Caplyta (lumateperone)

+

inotuzumab ozogamicin

1 interaction

Monitor/Modify Tx

lumateperone + inotuzumab ozogamicin

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• insulin
Caplyta (lumateperone)

+

insulin

1 interaction

Monitor/Modify Tx

lumateperone + insulin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• iohexol
Caplyta (lumateperone)

+

iohexol

1 interaction

Monitor/Modify Tx

lumateperone + iohexol

if intrathecal iohexol use, D/C lumateperone at least 48h before myelography, may resume at least 24h after procedure: combo may incr. risk of seizures (additive effects)

• iopamidol
Caplyta (lumateperone)

+

iopamidol

1 interaction

Monitor/Modify Tx

lumateperone + iopamidol

caution advised if intrathecal iopamidol use; consider holding lumateperone at least 48h before and at least 24h after intrathecal iopamidol: combo may incr. risk of seizures (additive effects)

• irbesartan
Caplyta (lumateperone)

+

irbesartan

1 interaction

Monitor/Modify Tx

lumateperone + irbesartan

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• iron sucrose
Caplyta (lumateperone)

+

iron sucrose

1 interaction

Monitor/Modify Tx

lumateperone + iron sucrose

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• isavuconazonium
Caplyta (lumateperone)

+

isavuconazonium

1 interaction

Monitor/Modify Tx

lumateperone + isavuconazonium

monitor ECG; decr. lumateperone dose to 21 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• isoflurane
Caplyta (lumateperone)

+

isoflurane

1 interaction

Monitor/Modify Tx

lumateperone + isoflurane

monitor ECG, BP, respiratory rate: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• isosorbide dinitrate
Caplyta (lumateperone)

+

isosorbide dinitrate

1 interaction

Monitor/Modify Tx

lumateperone + isosorbide dinitrate

monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

• isosorbide mononitrate
Caplyta (lumateperone)

+

isosorbide mononitrate

1 interaction

Monitor/Modify Tx

lumateperone + isosorbide mononitrate

monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

• isradipine
Caplyta (lumateperone)

+

isradipine

1 interaction

Monitor/Modify Tx

lumateperone + isradipine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• istradefylline
Caplyta (lumateperone)

+

istradefylline

1 interaction

Monitor/Modify Tx

lumateperone + istradefylline

monitor ECG, especially w/ istradefylline 40 mg dose: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• itraconazole
Caplyta (lumateperone)

+

itraconazole

1 interaction

Monitor/Modify Tx

lumateperone + itraconazole

monitor ECG; decr. lumateperone dose to 10.5 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• ivacaftor
Caplyta (lumateperone)

+

ivacaftor

1 interaction

Monitor/Modify Tx

lumateperone + ivacaftor

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• ketamine
Caplyta (lumateperone)

+

ketamine

1 interaction

Monitor/Modify Tx

lumateperone + ketamine

monitor respiratory rate; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression (including life-threatening), psychomotor impairment (additive effects)

• ketoconazole
Caplyta (lumateperone)

+

ketoconazole

1 interaction

Monitor/Modify Tx

lumateperone + ketoconazole

monitor ECG; decr. lumateperone dose to 10.5 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• labetalol
Caplyta (lumateperone)

+

labetalol

1 interaction

Monitor/Modify Tx

lumateperone + labetalol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• landiolol
Caplyta (lumateperone)

+

landiolol

1 interaction

Monitor/Modify Tx

lumateperone + landiolol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• lapatinib
Caplyta (lumateperone)

+

lapatinib

1 interaction

Monitor/Modify Tx

lumateperone + lapatinib

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• larotrectinib
Caplyta (lumateperone)

+

larotrectinib

1 interaction

Monitor/Modify Tx

lumateperone + larotrectinib

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• lazertinib
Caplyta (lumateperone)

+

lazertinib

1 interaction

Monitor/Modify Tx

lumateperone + lazertinib

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• lemborexant
Caplyta (lumateperone)

+

lemborexant

1 interaction

Monitor/Modify Tx

lumateperone + lemborexant

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• lenacapavir
Caplyta (lumateperone)

+

lenacapavir

1 interaction

Monitor/Modify Tx

lumateperone + lenacapavir

monitor ECG during and x9mo after lenacapavir tx; decr. lumateperone dose to 21 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• letermovir
Caplyta (lumateperone)

+

letermovir

1 interaction

Monitor/Modify Tx

lumateperone + letermovir

monitor ECG; decr. lumateperone dose to 21 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• leuprolide
Caplyta (lumateperone)

+

leuprolide

1 interaction

Monitor/Modify Tx

lumateperone + leuprolide

PROSTATE CANCER: monitor ECG, electrolytes; ALL OTHER INDICATIONS: consider monitoring ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• levobunolol ophthalmic
Caplyta (lumateperone)

+

levobunolol ophthalmic

1 interaction

Monitor/Modify Tx

lumateperone + levobunolol ophthalmic

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• levodopa
Caplyta (lumateperone)

+

levodopa

1 interaction

Monitor/Modify Tx

lumateperone + levodopa

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• levofloxacin
Caplyta (lumateperone)

+

levofloxacin

1 interaction

Monitor/Modify Tx

lumateperone + levofloxacin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• levoketoconazole
Caplyta (lumateperone)

+

levoketoconazole

1 interaction

Monitor/Modify Tx

lumateperone + levoketoconazole

monitor ECG; decr. lumateperone dose to 10.5 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• lidocaine
Caplyta (lumateperone)

+

lidocaine

1 interaction

Monitor/Modify Tx

lumateperone + lidocaine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• linagliptin
Caplyta (lumateperone)

+

linagliptin

1 interaction

Monitor/Modify Tx

lumateperone + linagliptin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• liraglutide
Caplyta (lumateperone)

+

liraglutide

1 interaction

Monitor/Modify Tx

lumateperone + liraglutide

monitor glucose in type 2 diabetes mellitus pts: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• lisinopril
Caplyta (lumateperone)

+

lisinopril

1 interaction

Monitor/Modify Tx

lumateperone + lisinopril

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• lixisenatide
Caplyta (lumateperone)

+

lixisenatide

1 interaction

Monitor/Modify Tx

lumateperone + lixisenatide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• lomitapide
Caplyta (lumateperone)

+

lomitapide

1 interaction

Monitor/Modify Tx

lumateperone + lomitapide

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• lorazepam
Caplyta (lumateperone)

+

lorazepam

1 interaction

Monitor/Modify Tx

lumateperone + lorazepam

monitor respiratory rate, BP; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope; may alter seizure control (additive effects; antagonistic effects, lumateperone may decr. seizure threshold)

• losartan
Caplyta (lumateperone)

+

losartan

1 interaction

Monitor/Modify Tx

lumateperone + losartan

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• lovastatin
Caplyta (lumateperone)

+

lovastatin

1 interaction

Monitor/Modify Tx

lumateperone + lovastatin

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• loxapine
Caplyta (lumateperone)

+

loxapine

1 interaction

Monitor/Modify Tx

lumateperone + loxapine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension, including orthostasis, syncope (additive effects)

• lubiprostone
Caplyta (lumateperone)

+

lubiprostone

1 interaction

Monitor/Modify Tx

lumateperone + lubiprostone

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• macimorelin
Caplyta (lumateperone)

+

macimorelin

1 interaction

Monitor/Modify Tx

lumateperone + macimorelin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• magnesium sulfate
Caplyta (lumateperone)

+

magnesium sulfate

1 interaction

Monitor/Modify Tx

lumateperone + magnesium sulfate

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• maraviroc
Caplyta (lumateperone)

+

maraviroc

1 interaction

Monitor/Modify Tx

lumateperone + maraviroc

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• maribavir
Caplyta (lumateperone)

+

maribavir

1 interaction

Monitor/Modify Tx

lumateperone + maribavir

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• mavorixafor
Caplyta (lumateperone)

+

mavorixafor

1 interaction

Monitor/Modify Tx

lumateperone + mavorixafor

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• mepivacaine
Caplyta (lumateperone)

+

mepivacaine

1 interaction

Monitor/Modify Tx

lumateperone + mepivacaine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• metformin
Caplyta (lumateperone)

+

metformin

1 interaction

Monitor/Modify Tx

lumateperone + metformin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• methohexital
Caplyta (lumateperone)

+

methohexital

1 interaction

Monitor/Modify Tx

lumateperone + methohexital

monitor BP, respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• methyldopa
Caplyta (lumateperone)

+

methyldopa

1 interaction

Monitor/Modify Tx

lumateperone + methyldopa

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• methylene blue injection
Caplyta (lumateperone)

+

methylene blue injection

1 interaction

Monitor/Modify Tx

lumateperone + methylene blue injection

hold lumateperone if emergency use; monitor BP, serotonin syndrome sx up to 4h after last methylene blue dose; may resume lumateperone 72h after last methylene blue dose: combo may incr. risk of serotonin syndrome, hypotension, including orthostasis, syncope (additive effects, methylene blue reversibly inhibits monoamine oxidase)

• methylene blue oral
Caplyta (lumateperone)

+

methylene blue oral

1 interaction

Monitor/Modify Tx

lumateperone + methylene blue oral

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects, methylene blue reversibly inhibits monoamine oxidase)

• methylergonovine
Caplyta (lumateperone)

+

methylergonovine

1 interaction

Monitor/Modify Tx

lumateperone + methylergonovine

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• methylphenidate
Caplyta (lumateperone)

+

methylphenidate

1 interaction

Monitor/Modify Tx

lumateperone + methylphenidate

monitor serotonin syndrome symptoms, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• metolazone
Caplyta (lumateperone)

+

metolazone

1 interaction

Monitor/Modify Tx

lumateperone + metolazone

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• metoprolol
Caplyta (lumateperone)

+

metoprolol

1 interaction

Monitor/Modify Tx

lumateperone + metoprolol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• mifepristone
Caplyta (lumateperone)

+

mifepristone

1 interaction

Monitor/Modify Tx

lumateperone + mifepristone

monitor ECG; decr. lumateperone dose to 10.5 mg qd during and x14 days after daily mifepristone use: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• miglitol
Caplyta (lumateperone)

+

miglitol

1 interaction

Monitor/Modify Tx

lumateperone + miglitol

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• milrinone
Caplyta (lumateperone)

+

milrinone

1 interaction

Monitor/Modify Tx

lumateperone + milrinone

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• minoxidil
Caplyta (lumateperone)

+

minoxidil

1 interaction

Monitor/Modify Tx

lumateperone + minoxidil

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• moexipril
Caplyta (lumateperone)

+

moexipril

1 interaction

Monitor/Modify Tx

lumateperone + moexipril

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• molindone
Caplyta (lumateperone)

+

molindone

1 interaction

Monitor/Modify Tx

lumateperone + molindone

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension, including orthostasis, syncope (additive effects)

• moxifloxacin
Caplyta (lumateperone)

+

moxifloxacin

1 interaction

Monitor/Modify Tx

lumateperone + moxifloxacin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• nadolol
Caplyta (lumateperone)

+

nadolol

1 interaction

Monitor/Modify Tx

lumateperone + nadolol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• naratriptan
Caplyta (lumateperone)

+

naratriptan

1 interaction

Monitor/Modify Tx

lumateperone + naratriptan

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome (additive effects)

• nateglinide
Caplyta (lumateperone)

+

nateglinide

1 interaction

Monitor/Modify Tx

lumateperone + nateglinide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• nattokinase
Caplyta (lumateperone)

+

nattokinase

1 interaction

Monitor/Modify Tx

lumateperone + nattokinase

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• naxitamab
Caplyta (lumateperone)

+

naxitamab

1 interaction

Monitor/Modify Tx

lumateperone + naxitamab

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• nebivolol
Caplyta (lumateperone)

+

nebivolol

1 interaction

Monitor/Modify Tx

lumateperone + nebivolol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• nefazodone
Caplyta (lumateperone)

+

nefazodone

1 interaction

Monitor/Modify Tx

lumateperone + nefazodone

monitor ECG, serotonin syndrome sx, especially during initiation/titration; decr. lumateperone dose to 10.5 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, serotonin syndrome, other adverse effects (hepatic metabolism inhibited, additive effects)

• nelarabine
Caplyta (lumateperone)

+

nelarabine

1 interaction

Monitor/Modify Tx

lumateperone + nelarabine

withhold nelarabine if Grade 2 or greater somnolence occurs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• nelfinavir
Caplyta (lumateperone)

+

nelfinavir

1 interaction

Monitor/Modify Tx

lumateperone + nelfinavir

monitor ECG; decr. lumateperone dose to 10.5 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• niacin (vitamin B3)
Caplyta (lumateperone)

+

niacin (vitamin B3)

1 interaction

Monitor/Modify Tx

lumateperone + niacin (vitamin B3)

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• nicardipine
Caplyta (lumateperone)

+

nicardipine

1 interaction

Monitor/Modify Tx

lumateperone + nicardipine

monitor ECG, BP: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited, additive effects)

• nifedipine
Caplyta (lumateperone)

+

nifedipine

1 interaction

Monitor/Modify Tx

lumateperone + nifedipine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• nilotinib
Caplyta (lumateperone)

+

nilotinib

1 interaction

Monitor/Modify Tx

lumateperone + nilotinib

monitor ECG, electrolytes; decr. lumateperone dose to 21 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• nimodipine
Caplyta (lumateperone)

+

nimodipine

1 interaction

Monitor/Modify Tx

lumateperone + nimodipine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• nirogacestat
Caplyta (lumateperone)

+

nirogacestat

1 interaction

Monitor/Modify Tx

lumateperone + nirogacestat

monitor ECG; decr. lumateperone dose to 21 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• nisoldipine
Caplyta (lumateperone)

+

nisoldipine

1 interaction

Monitor/Modify Tx

lumateperone + nisoldipine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• nitric oxide
Caplyta (lumateperone)

+

nitric oxide

1 interaction

Monitor/Modify Tx

lumateperone + nitric oxide

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• nitrite
Caplyta (lumateperone)

+

nitrite

1 interaction

Monitor/Modify Tx

lumateperone + nitrite

monitor BP: combo may incr. risk of severe or life-threatening hypotension, including orthostasis, syncope (additive effects)

• nitroglycerin
Caplyta (lumateperone)

+

nitroglycerin

1 interaction

Monitor/Modify Tx

lumateperone + nitroglycerin

monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

• nitroprusside
Caplyta (lumateperone)

+

nitroprusside

1 interaction

Monitor/Modify Tx

lumateperone + nitroprusside

monitor BP: combo may incr. risk of severe or life-threatening hypotension, including orthostasis, syncope (additive effects)

• obinutuzumab
Caplyta (lumateperone)

+

obinutuzumab

1 interaction

Monitor/Modify Tx

lumateperone + obinutuzumab

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• olmesartan medoxomil
Caplyta (lumateperone)

+

olmesartan medoxomil

1 interaction

Monitor/Modify Tx

lumateperone + olmesartan medoxomil

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• opicapone
Caplyta (lumateperone)

+

opicapone

1 interaction

Monitor/Modify Tx

lumateperone + opicapone

monitor BP; consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• osilodrostat
Caplyta (lumateperone)

+

osilodrostat

1 interaction

Monitor/Modify Tx

lumateperone + osilodrostat

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• osimertinib
Caplyta (lumateperone)

+

osimertinib

1 interaction

Monitor/Modify Tx

lumateperone + osimertinib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• oxazepam
Caplyta (lumateperone)

+

oxazepam

1 interaction

Monitor/Modify Tx

lumateperone + oxazepam

monitor BP, respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• oxybutynin
Caplyta (lumateperone)

+

oxybutynin

1 interaction

Monitor/Modify Tx

lumateperone + oxybutynin

decr. dose of one or both drugs or consider oxybutynin transdermal patch: combo may incr. risk of CNS depression, psychomotor impairment, hyperthermia; somnolence less likely with oxybutynin transdermal patch (additive effects)

• palbociclib
Caplyta (lumateperone)

+

palbociclib

1 interaction

Monitor/Modify Tx

lumateperone + palbociclib

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• palonosetron
Caplyta (lumateperone)

+

palonosetron

1 interaction

Monitor/Modify Tx

lumateperone + palonosetron

monitor ECG, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of QT prolongation, cardiac arrhythmias, serotonin syndrome (additive effects)

• palopegteriparatide
Caplyta (lumateperone)

+

palopegteriparatide

1 interaction

Monitor/Modify Tx

lumateperone + palopegteriparatide

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• pasireotide
Caplyta (lumateperone)

+

pasireotide

1 interaction

Monitor/Modify Tx

lumateperone + pasireotide

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pazopanib
Caplyta (lumateperone)

+

pazopanib

1 interaction

Monitor/Modify Tx

lumateperone + pazopanib

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• pentamidine
Caplyta (lumateperone)

+

pentamidine

1 interaction

Monitor/Modify Tx

lumateperone + pentamidine

monitor ECG, BP; risk may be lower w/ nebulized pentamidine: combo may incr. risk of QT prolongation, cardiac arrhythmias, severe or life-threatening hypotension, including orthostasis, syncope (additive effects)

• peppermint
Caplyta (lumateperone)

+

peppermint

1 interaction

Monitor/Modify Tx

lumateperone + peppermint

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• perindopril
Caplyta (lumateperone)

+

perindopril

1 interaction

Monitor/Modify Tx

lumateperone + perindopril

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• perphenazine
Caplyta (lumateperone)

+

perphenazine

1 interaction

Monitor/Modify Tx

lumateperone + perphenazine

monitor BP, consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, severe hypotension, including orthostasis, syncope (additive effects)

• phenoxybenzamine
Caplyta (lumateperone)

+

phenoxybenzamine

1 interaction

Monitor/Modify Tx

lumateperone + phenoxybenzamine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• phentolamine
Caplyta (lumateperone)

+

phentolamine

1 interaction

Monitor/Modify Tx

lumateperone + phentolamine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• pibrentasvir
Caplyta (lumateperone)

+

pibrentasvir

1 interaction

Monitor/Modify Tx

lumateperone + pibrentasvir

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• pindolol
Caplyta (lumateperone)

+

pindolol

1 interaction

Monitor/Modify Tx

lumateperone + pindolol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• pirtobrutinib
Caplyta (lumateperone)

+

pirtobrutinib

1 interaction

Monitor/Modify Tx

lumateperone + pirtobrutinib

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• posaconazole
Caplyta (lumateperone)

+

posaconazole

1 interaction

Monitor/Modify Tx

lumateperone + posaconazole

monitor ECG; decr. lumateperone dose to 10.5 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• pramipexole
Caplyta (lumateperone)

+

pramipexole

1 interaction

Monitor/Modify Tx

lumateperone + pramipexole

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• pramlintide
Caplyta (lumateperone)

+

pramlintide

1 interaction

Monitor/Modify Tx

lumateperone + pramlintide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• prazosin
Caplyta (lumateperone)

+

prazosin

1 interaction

Monitor/Modify Tx

lumateperone + prazosin

monitor BP, especially during prazosin initiation/titration: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• pregabalin
Caplyta (lumateperone)

+

pregabalin

1 interaction

Monitor/Modify Tx

lumateperone + pregabalin

monitor respiratory rate: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, lumateperone may decr. seizure threshold)

• primaquine
Caplyta (lumateperone)

+

primaquine

1 interaction

Monitor/Modify Tx

lumateperone + primaquine

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism possibly inhibited)

• procainamide
Caplyta (lumateperone)

+

procainamide

1 interaction

Monitor/Modify Tx

lumateperone + procainamide

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• prochlorperazine
Caplyta (lumateperone)

+

prochlorperazine

1 interaction

Monitor/Modify Tx

lumateperone + prochlorperazine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension, including orthostasis, syncope (additive effects)

• propafenone
Caplyta (lumateperone)

+

propafenone

1 interaction

Monitor/Modify Tx

lumateperone + propafenone

monitor ECG, BP: combo may incr. risk of QT prolongation, cardiac arrhythmias, hypotension, including orthostasis, syncope (additive effects)

• propofol
Caplyta (lumateperone)

+

propofol

1 interaction

Monitor/Modify Tx

lumateperone + propofol

monitor BP, respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope (additive effects)

• propranolol
Caplyta (lumateperone)

+

propranolol

1 interaction

Monitor/Modify Tx

lumateperone + propranolol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• protriptyline
Caplyta (lumateperone)

+

protriptyline

1 interaction

Monitor/Modify Tx

lumateperone + protriptyline

monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, hypotension (including orthostasis, syncope), hyperthermia, serotonin syndrome (additive effects)

• quazepam
Caplyta (lumateperone)

+

quazepam

1 interaction

Monitor/Modify Tx

lumateperone + quazepam

monitor BP, respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• quercetin
Caplyta (lumateperone)

+

quercetin

1 interaction

Monitor/Modify Tx

lumateperone + quercetin

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• quinapril
Caplyta (lumateperone)

+

quinapril

1 interaction

Monitor/Modify Tx

lumateperone + quinapril

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• quinidine (antiarrhythmic)
Caplyta (lumateperone)

+

quinidine (antiarrhythmic)

1 interaction

Monitor/Modify Tx

lumateperone + quinidine (antiarrhythmic)

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• quinidine (CYP2D6 inhibitor)
Caplyta (lumateperone)

+

quinidine (CYP2D6 inhibitor)

1 interaction

Monitor/Modify Tx

lumateperone + quinidine (CYP2D6 inhibitor)

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• quinine
Caplyta (lumateperone)

+

quinine

1 interaction

Monitor/Modify Tx

lumateperone + quinine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ramipril
Caplyta (lumateperone)

+

ramipril

1 interaction

Monitor/Modify Tx

lumateperone + ramipril

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• ranolazine
Caplyta (lumateperone)

+

ranolazine

1 interaction

Monitor/Modify Tx

lumateperone + ranolazine

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• remdesivir
Caplyta (lumateperone)

+

remdesivir

1 interaction

Monitor/Modify Tx

lumateperone + remdesivir

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• remimazolam
Caplyta (lumateperone)

+

remimazolam

1 interaction

Monitor/Modify Tx

lumateperone + remimazolam

monitor BP, respiratory rate; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of hypotension (including orthostasis, syncope), profound CNS and respiratory depression, psychomotor impairment (additive effects)

• repaglinide
Caplyta (lumateperone)

+

repaglinide

1 interaction

Monitor/Modify Tx

lumateperone + repaglinide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• resveratrol
Caplyta (lumateperone)

+

resveratrol

1 interaction

Monitor/Modify Tx

lumateperone + resveratrol

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• revumenib
Caplyta (lumateperone)

+

revumenib

1 interaction

Monitor/Modify Tx

lumateperone + revumenib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ribociclib
Caplyta (lumateperone)

+

ribociclib

1 interaction

Monitor/Modify Tx

lumateperone + ribociclib

monitor ECG, electrolytes; decr. lumateperone dose to 10.5 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• rilzabrutinib
Caplyta (lumateperone)

+

rilzabrutinib

1 interaction

Monitor/Modify Tx

lumateperone + rilzabrutinib

monitor ECG; decr. lumateperone dose to 21 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• riociguat
Caplyta (lumateperone)

+

riociguat

1 interaction

Monitor/Modify Tx

lumateperone + riociguat

monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

• ritlecitinib
Caplyta (lumateperone)

+

ritlecitinib

1 interaction

Monitor/Modify Tx

lumateperone + ritlecitinib

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• ritonavir
Caplyta (lumateperone)

+

ritonavir

1 interaction

Monitor/Modify Tx

lumateperone + ritonavir

monitor ECG; decr. lumateperone dose to 10.5 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• rizatriptan
Caplyta (lumateperone)

+

rizatriptan

1 interaction

Monitor/Modify Tx

lumateperone + rizatriptan

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome (additive effects)

• romidepsin
Caplyta (lumateperone)

+

romidepsin

1 interaction

Monitor/Modify Tx

lumateperone + romidepsin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ropinirole
Caplyta (lumateperone)

+

ropinirole

1 interaction

Monitor/Modify Tx

lumateperone + ropinirole

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• ropivacaine
Caplyta (lumateperone)

+

ropivacaine

1 interaction

Monitor/Modify Tx

lumateperone + ropivacaine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• rosiglitazone
Caplyta (lumateperone)

+

rosiglitazone

1 interaction

Monitor/Modify Tx

lumateperone + rosiglitazone

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• rotigotine transdermal
Caplyta (lumateperone)

+

rotigotine transdermal

1 interaction

Monitor/Modify Tx

lumateperone + rotigotine transdermal

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, including orthostasis, syncope; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• rucaparib
Caplyta (lumateperone)

+

rucaparib

1 interaction

Monitor/Modify Tx

lumateperone + rucaparib

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• sacubitril
Caplyta (lumateperone)

+

sacubitril

1 interaction

Monitor/Modify Tx

lumateperone + sacubitril

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• SAMe
Caplyta (lumateperone)

+

SAMe

1 interaction

Monitor/Modify Tx

lumateperone + SAMe

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• saxagliptin
Caplyta (lumateperone)

+

saxagliptin

1 interaction

Monitor/Modify Tx

lumateperone + saxagliptin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• selpercatinib
Caplyta (lumateperone)

+

selpercatinib

1 interaction

Monitor/Modify Tx

lumateperone + selpercatinib

monitor ECG, electrolytes: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• semaglutide
Caplyta (lumateperone)

+

semaglutide

1 interaction

Monitor/Modify Tx

lumateperone + semaglutide

monitor glucose in type 2 diabetes mellitus pts: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• sevabertinib
Caplyta (lumateperone)

+

sevabertinib

1 interaction

Monitor/Modify Tx

lumateperone + sevabertinib

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• sevoflurane
Caplyta (lumateperone)

+

sevoflurane

1 interaction

Monitor/Modify Tx

lumateperone + sevoflurane

monitor ECG, BP, respiratory rate: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• sildenafil
Caplyta (lumateperone)

+

sildenafil

1 interaction

Monitor/Modify Tx

lumateperone + sildenafil

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• silodosin
Caplyta (lumateperone)

+

silodosin

1 interaction

Monitor/Modify Tx

lumateperone + silodosin

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• sitagliptin
Caplyta (lumateperone)

+

sitagliptin

1 interaction

Monitor/Modify Tx

lumateperone + sitagliptin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• sodium ferric gluconate complex
Caplyta (lumateperone)

+

sodium ferric gluconate complex

1 interaction

Monitor/Modify Tx

lumateperone + sodium ferric gluconate complex

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• sotagliflozin
Caplyta (lumateperone)

+

sotagliflozin

1 interaction

Monitor/Modify Tx

lumateperone + sotagliflozin

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• sparsentan
Caplyta (lumateperone)

+

sparsentan

1 interaction

Monitor/Modify Tx

lumateperone + sparsentan

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• spironolactone
Caplyta (lumateperone)

+

spironolactone

1 interaction

Monitor/Modify Tx

lumateperone + spironolactone

monitor ECG, BP: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism possibly inhibited, additive effects)

• sumatriptan
Caplyta (lumateperone)

+

sumatriptan

1 interaction

Monitor/Modify Tx

lumateperone + sumatriptan

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome (additive effects)

• suvorexant
Caplyta (lumateperone)

+

suvorexant

1 interaction

Monitor/Modify Tx

lumateperone + suvorexant

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tadalafil
Caplyta (lumateperone)

+

tadalafil

1 interaction

Monitor/Modify Tx

lumateperone + tadalafil

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• tagraxofusp
Caplyta (lumateperone)

+

tagraxofusp

1 interaction

Monitor/Modify Tx

lumateperone + tagraxofusp

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• taletrectinib
Caplyta (lumateperone)

+

taletrectinib

1 interaction

Monitor/Modify Tx

lumateperone + taletrectinib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• tamsulosin
Caplyta (lumateperone)

+

tamsulosin

1 interaction

Monitor/Modify Tx

lumateperone + tamsulosin

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• taurine
Caplyta (lumateperone)

+

taurine

1 interaction

Monitor/Modify Tx

lumateperone + taurine

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• tedizolid
Caplyta (lumateperone)

+

tedizolid

1 interaction

Monitor/Modify Tx

lumateperone + tedizolid

monitor serotonin syndrome symptoms, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects, tedizolid reversibly inhibits monoamine oxidase)

• telavancin
Caplyta (lumateperone)

+

telavancin

1 interaction

Monitor/Modify Tx

lumateperone + telavancin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• telmisartan
Caplyta (lumateperone)

+

telmisartan

1 interaction

Monitor/Modify Tx

lumateperone + telmisartan

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• temazepam
Caplyta (lumateperone)

+

temazepam

1 interaction

Monitor/Modify Tx

lumateperone + temazepam

monitor BP, respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• terazosin
Caplyta (lumateperone)

+

terazosin

1 interaction

Monitor/Modify Tx

lumateperone + terazosin

monitor BP, especially during terazosin initiation/titration: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• tetrabenazine
Caplyta (lumateperone)

+

tetrabenazine

1 interaction

Monitor/Modify Tx

lumateperone + tetrabenazine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment (additive effects)

• thiothixene
Caplyta (lumateperone)

+

thiothixene

1 interaction

Monitor/Modify Tx

lumateperone + thiothixene

monitor BP, consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, hypotension, including orthostasis, syncope (additive effects)

• ticagrelor
Caplyta (lumateperone)

+

ticagrelor

1 interaction

Monitor/Modify Tx

lumateperone + ticagrelor

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• timolol
Caplyta (lumateperone)

+

timolol

1 interaction

Monitor/Modify Tx

lumateperone + timolol

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• timolol ophthalmic
Caplyta (lumateperone)

+

timolol ophthalmic

1 interaction

Monitor/Modify Tx

lumateperone + timolol ophthalmic

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• tipranavir
Caplyta (lumateperone)

+

tipranavir

1 interaction

Monitor/Modify Tx

lumateperone + tipranavir

monitor ECG; decr. lumateperone dose to 10.5 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• tirzepatide
Caplyta (lumateperone)

+

tirzepatide

1 interaction

Monitor/Modify Tx

lumateperone + tirzepatide

monitor glucose if type 2 diabetes mellitus use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• tizanidine
Caplyta (lumateperone)

+

tizanidine

1 interaction

Monitor/Modify Tx

lumateperone + tizanidine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• tolcapone
Caplyta (lumateperone)

+

tolcapone

1 interaction

Monitor/Modify Tx

lumateperone + tolcapone

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• tolvaptan
Caplyta (lumateperone)

+

tolvaptan

1 interaction

Monitor/Modify Tx

lumateperone + tolvaptan

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• torsemide
Caplyta (lumateperone)

+

torsemide

1 interaction

Monitor/Modify Tx

lumateperone + torsemide

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• trandolapril
Caplyta (lumateperone)

+

trandolapril

1 interaction

Monitor/Modify Tx

lumateperone + trandolapril

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• trazodone
Caplyta (lumateperone)

+

trazodone

1 interaction

Monitor/Modify Tx

lumateperone + trazodone

monitor BP, sodium, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, hypotension (including orthostasis, syncope), hyponatremia, serotonin syndrome (additive effects)

• treosulfan
Caplyta (lumateperone)

+

treosulfan

1 interaction

Monitor/Modify Tx

lumateperone + treosulfan

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, seizures, other adverse effects (hepatic metabolism possibly inhibited, additive effects)

• treprostinil
Caplyta (lumateperone)

+

treprostinil

1 interaction

Monitor/Modify Tx

lumateperone + treprostinil

monitor BP: combo may incr. risk of severe hypotension, including orthostasis, syncope (additive effects)

• triamterene
Caplyta (lumateperone)

+

triamterene

1 interaction

Monitor/Modify Tx

lumateperone + triamterene

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• triazolam
Caplyta (lumateperone)

+

triazolam

1 interaction

Monitor/Modify Tx

lumateperone + triazolam

monitor BP, respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment, hypotension, including orthostasis, syncope (additive effects)

• triclabendazole
Caplyta (lumateperone)

+

triclabendazole

1 interaction

Monitor/Modify Tx

lumateperone + triclabendazole

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• trifluoperazine
Caplyta (lumateperone)

+

trifluoperazine

1 interaction

Monitor/Modify Tx

lumateperone + trifluoperazine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, extrapyramidal symptoms, hyperthermia, severe hypotension, including orthostasis, syncope (additive effects)

• trifluridine
Caplyta (lumateperone)

+

trifluridine

1 interaction

Monitor/Modify Tx

lumateperone + trifluridine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• triptorelin
Caplyta (lumateperone)

+

triptorelin

1 interaction

Monitor/Modify Tx

lumateperone + triptorelin

PROSTATE CANCER: monitor ECG, electrolytes; ALL OTHER INDICATIONS: consider monitoring ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• trofinetide
Caplyta (lumateperone)

+

trofinetide

1 interaction

Monitor/Modify Tx

lumateperone + trofinetide

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (GI metabolism inhibited)

• tucatinib
Caplyta (lumateperone)

+

tucatinib

1 interaction

Monitor/Modify Tx

lumateperone + tucatinib

monitor ECG; decr. lumateperone dose to 10.5 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• valsartan
Caplyta (lumateperone)

+

valsartan

1 interaction

Monitor/Modify Tx

lumateperone + valsartan

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• vardenafil
Caplyta (lumateperone)

+

vardenafil

1 interaction

Monitor/Modify Tx

lumateperone + vardenafil

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• verapamil
Caplyta (lumateperone)

+

verapamil

1 interaction

Monitor/Modify Tx

lumateperone + verapamil

monitor BP, ECG; decr. lumateperone dose to 21 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited, additive effects)

• viloxazine
Caplyta (lumateperone)

+

viloxazine

1 interaction

Monitor/Modify Tx

lumateperone + viloxazine

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

• vonoprazan
Caplyta (lumateperone)

+

vonoprazan

1 interaction

Monitor/Modify Tx

lumateperone + vonoprazan

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• voriconazole
Caplyta (lumateperone)

+

voriconazole

1 interaction

Monitor/Modify Tx

lumateperone + voriconazole

monitor ECG; decr. lumateperone dose to 10.5 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• vosoritide
Caplyta (lumateperone)

+

vosoritide

1 interaction

Monitor/Modify Tx

lumateperone + vosoritide

monitor BP: combo may incr. risk of hypotension, including orthostasis, syncope (additive effects)

• xanomeline
Caplyta (lumateperone)

+

xanomeline

1 interaction

Monitor/Modify Tx

lumateperone + xanomeline

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (GI metabolism possibly inhibited)

• yohimbe
Caplyta (lumateperone)

+

yohimbe

1 interaction

Monitor/Modify Tx

lumateperone + yohimbe

monitor BP, especially w/ high yohimbe doses, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, hypotension, including orthostasis, syncope (additive effects)

• zaleplon
Caplyta (lumateperone)

+

zaleplon

1 interaction

Monitor/Modify Tx

lumateperone + zaleplon

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ziconotide
Caplyta (lumateperone)

+

ziconotide

1 interaction

Monitor/Modify Tx

lumateperone + ziconotide

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ziftomenib
Caplyta (lumateperone)

+

ziftomenib

1 interaction

Monitor/Modify Tx

lumateperone + ziftomenib

monitor ECG, electrolytes: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

• zileuton
Caplyta (lumateperone)

+

zileuton

1 interaction

Monitor/Modify Tx

lumateperone + zileuton

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• zolmitriptan
Caplyta (lumateperone)

+

zolmitriptan

1 interaction

Monitor/Modify Tx

lumateperone + zolmitriptan

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of CNS depression, psychomotor impairment, serotonin syndrome (additive effects)

• zolpidem
Caplyta (lumateperone)

+

zolpidem

1 interaction

Monitor/Modify Tx

lumateperone + zolpidem

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)